AU2005237174B2 - Rescue of mumps virus from CDNA - Google Patents

Description

1

AUSTRALIA

Patents Act COMPLETE SPECIFICATION

(ORIGINAL)

Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: Wyeth Actual Inventor(s): David K. Clarke, Erik J. Johnson, Mohinderjit S. Sidhu, Stephen A. Udem Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: RESCUE OF MMPS VIUS FROM CDNA Our Ref 760329 POF Code: 49377/460161 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): -1- 6006q 1A O RESCUE OF MUMPS VIRUS FROM cDNA n The present application is a divisional application from Australian patent application Cr No. 65149/00, the entire disclosure of which is incorporated herein by reference.

Field of the Invention C^ This invention relates to a method for recombinantly producing n mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and

O

0 immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes in the genome are obtained. This inventfn also relates to use of the recombinant virus formed therefrom as vector for expressing foreign genetic information, e.g. foreign genes, for many applications, including immunogenic or pharmaceutical compositions for pathogens other than mumps, gene therapy, nd cell targeting.

Background Of The Invention Enveloped, negative-sense, single stranded RNA viruses are uniquely organized and expressed. The genomic RNA of negative-sense, single stranded viruses serves two template functions in the context of a nucleocapsid: as a template for the synthesis of messenger RNAs (mRNAs) and as a template for the synthesis of the antigenome strand. Negative-sense, single stranded RNA viruses encode and package their own RNA-dependent RNA Polymerase.

Messenger RNAs are only synthesized once the virus has entered the cytoplasm of the infected cell. Viral replication occurs after synthesis of the mRNAs and requires the continuous synthesis of viral proteins. The newly synthesized antigenome strand serves as the template for generating further copies of the strand genomic RNA.

C WO 01/09309 PCT/US00/21192 S2 The etiological agent of mumps was first shown reproducibly to be a Svirus by Johnson and Goodpasture in 1935 (Johnson and Goodpasture, 1935).

S Since then, propagation in tissue culture has facilitated virus classification and studies on the biological properties of mumps virus (MUV). Originally classified with influenza viruses in the Myxovirus family, mumps virus has since been re-assigned to the Paramyxoviridae family, subfamily Paramyxovirinae, genus Rubulavirus, based on nucleocapsid morphology, genome organization and biological properties of the proteins. Other examples of the Rubulavirus genus include simian virus 5 (SV5), human parainfluenza virus type 2 and type 4 and Newcastle disease virus (Lamb and Kolakofsky, 1996). Like all viruses of the Paramyxoviridae, mumps virus is pleomorphic in shape, comprising a host cell derived lipid membrane surrounding a ribonucleoprotein core; this nucleocapsid core forms a helical structure composed of a 15,384 nucleotide nonsegmented negative sense RNA genome closely associated with virus nucleocapsid protein The genetic organization of the MUV genome has been determined to be 3'-NP-P-M-F-SH- (Elango et al., 1998). Each gene encodes a single protein except for the P cistron, from which three unique mRNAs are transcribed; one is a faithful copy of the P gene, encoding the V protein, the two other mRNAs contain two and four non-templated G residues inserted during transcription by a RNA editing mechanism, and encode the P and I proteins respectively(Paterson and Lamb, 1990). The P and L proteins in association with nucleocapsid form the functional RNA polymerase complex of mumps virus. The F and HN proteins are integral membrane proteins which project from the surface of the virion, and are involved in virus attachment and entry of cells. The small hydrophobic protein (SH) and matrix protein are also membrane associated (Takeuchi et al, 1996 and Lamb and Kolakofsky, 1996); the role of the V and I proteins in virus growth is not yet clear.

WO 01/09309 PCT/US00/21192 S3 The replicative cycle of mumps virus initiates upon fusion of virus envelope with host cell plasma membrane and subsequent release of virus nucleocapsid into the cell cytoplasm. Primary transcription then ensues, resulting in the production of all virus proteins; a switch to replication of the virus genome occurs later, followed by assembly of virus components to form t new virus particles which bud from the host cell plasma membrane. Only the Sintact nucleocapsid structure can act as the template for RNA transcription, replication and subsequent virus amplification; therein lies the difficulty in genetic manipulation of MUV and other negative strand RNA viruses. Unlike the positive strand RNA viruses where naked genomic RNA is infectious and infectious virus can be recovered from a cDNA copy of the genome in the absence of additional viral factors (Taniguchi et al., 1978; Racaniello and Baltimore, 1981), the naked genome of negative strand RNA viruses is not infectious and rescue of virus from cDNA requires intracellular co-expression of viral NP, P and L proteins, along with a full length positive sense, or negative sense, genome RNA transcript, all under control of the bacteriophage T7 RNA polymerase promoter (Schnell et al., 1994; Lawson et al. 1995; Whelan et al., 1995; Radecke et al., 1995; Collins et al., 1995; Hoffman and Banerjee, 1997; Durbin et al., 1997; He et al., 1997; Baron and Barrett, 1997; Jin et al., 1998; Buchholz et al., 1999; Peeters et al., 1999). In all of the reported systems T7 RNA polymerase has been supplied either by a coinfecting recombinant vaccinia virus (Fuerst et al., 1986; Wyatt et al., 1995), or by endogenous expression of T7 RNA polymerase in a transformed cell line (Radecke et al., 1995).

The polymerase complex actuates and achieves transcription and replication by engaging the cis-acting signals at the 3' end of the genome, in particular, the promoter region. Viral genes are then transcribed from the genome template unidirectionally from its 3' to its 5' end. There is generally less mRNA made from the downstream genes the polymerase gene WO 01/09309 PCT/US00/21192 4 relative to their upstream neighbors the nucleoprotein gene Therefore, there is always a gradient of mRNA abundance according to the position of the genes relative to the 3'-end of the genome.

O 5 Molecular genetic analysis of such nonsegmented RNA viruses has C1 proved difficult until recently because naked genomic RNA or RNA produced intracellularly from a transfected plasmid is not infectious (Boyer and Haenni, 1994). These methods are referred to herein as "rescue". There are publications on methods of manipulating cDNA rescue methods that permit isolation of some recombinant nonsegmented, negative-strand RNA viruses (Schnell et al., 1994). The techniques for rescue of these different negativestrand viruses follows a common theme; however, each virus has distinguishing requisite components for successful rescue (Baron and Barrett, 1997; Collins et al., 1995; Garcin et al., 1995; Hoffman and Banerjee, 1997; Lawson et al., 1995; Radecke et al., 1995; Schneider et al., 1997; He et al, 1997; Schnell et al., 1994; Whelan et al., 1995). After transfection of a genomic cDNA plasmid, an exact copy of genome RNA is produced by the combined action of phage T7 RNA polymerase and a vector-encoded ribozyme sequence that cleaves the RNA to form the 3' termini. This RNA is packaged and replicated by viral proteins initially supplied by co-transfected expression plasmids. In the case of the mumps virus, a method of rescue has yet to be established and accordingly, there is a need to devise a method of mumps rescue. Devising a method of rescue for mumps virus is complicated by the absence of extensive studies on the biology of mumps virus, as compared with studies on other RNA viruses. Also, mumps virus does not grow efficiently in tissue culture systems.

Furthermore, the sequence for the termini of the mumps virus genome has not previously been characterized in sufficient detail for conducting rescue.

For successful rescue of mumps virus from cDNA to be achieved, numerous molecular events must occur after transfection, including: 1) WO 01/09309 PCT/USOO/21192 Iaccurate, full-length synthesis of genome or antigenome RNA by T7 RNA polymerase and 3' end processing by the ribozyme sequence; 2) synthesis of viral NP, P, and L proteins at levels appropriate to initiate replication; 3) the de novo packaging of genomic RNA into transcriptionally-active and replicationcompetent nucleocapsid structures; and 4) expression of viral genes from newly-formed nucleocapsids at levels- sufficient for replication to progress.

The present invention provides for a rescue method of recombinantly producing mumps virus. The rescued mumps virus possesses numerous uses, such as antibody generation, diagnostic, prophylactic and therapeutic applications, cell targeting, mutant virus preparation and immunogenic composition preparation. Furthermore, there are a number of advantages to using a recombinantly produced Jeryl Lynn strain of mumps for these applications. Some of these advantages include an attenuated phenotype, (2) a substantial safety record based on the over 100 million dosages administered, the ability to induce long-lasting immunity with a single dose and a relatively low level of genome recombination.

0 Throughout the description and claims of this specification, use of the word O "comprise" and variations of the word, such as "comprising" and "comprises", is not Z intended to exclude other additives, components, integers or steps.

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters Sformed part of the prior art base or were common general knowledge in the field S relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

Summary of the Invention The present invention provides for a method for producing a recombinant mumps virus comprising, in at least one host cell, conducting transfection of a rescue composition which comprises a transcription vector comprising an isolated nucleic acid molecule which comprises a polynucleotide sequence encoding a genome or antigenome of a mumps virus and (ii) at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins necessary for encapsidation, transcription and replication. The transfection is conducted under conditions sufficient to permit the co-expression of these vectors and the production of the recombinant virus. The recombinant virus is then harvested.

WVBmnendr11tfee1473 Wyt speodoc WO 01/09309 PCTIUS00/21192 S6 F1- Additional embodiments relate to the nucleotide sequences, which upon mRNA transcription express one or more, or any combination of, the following proteins of the mumps virus: NP, M, F, SH, HN L and the V, P, and I Sproteins which are generated from the P "cistron" of mumps virus as noted above. Related embodiments relate to nucleic acid molecules which comprise such nucleotide sequences. A preferred embodiment of this invention are the nucleotide sequences of SEQ ID NOS. 1, 11 and 12. Further embodiments relate to these nucleotides, the amino acids sequences of the above mumps virus proteins and variants thereof.

The protein and nucleotide sequences of this invention possess diagnostic, prophylactic and therapeutic utility for mumps virus. These sequences can be used to design screening systems for compounds that interfere or disrupt normal virus development, via encapsidation, replication, or amplification. The nucleotide sequence can also be used in the preparation of immunogenic compositions for mumps virus and/or for other pathogens when used to express foreign genes. In addition,, the foreign genes expressed may have therapeutic application.

In preferred embodiments, infectious recombinant virus is produced for use in immunogenic compositions and methods of treating or preventing infection by mumps virus and/or infection by other pathogens, wherein the method employs such compositions. 2

I

In alternative embodiments, this invention provides a method for generating recombinant mumps virus which is attenuated, infectious or both.

The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes in the genome can be obtained. Further 6. AUG. 2008 16:35 PHILLIPS ORMOND NO. 617 P. 11 00 7 0 Sembodiments employ the consensus genome sequence and/or any of the genome sequences Swithin the population of the Jeryl Lynn strain of mumps to express foreign genes since this licensed vaccine strain includes an established attenuated phenotype for safety. Since the consensus sequence is derived from a proposed average of the genomes of mumps virus, the polynucleotide sequences for the genomes within the population of the Jeryl Lynn strain are embodiments of this invention.

SThis invention also relates to use of the recombinant virus formed therefrom as vectors for expressing foreign genetic information, e. g. foreign genes, for many applications, including immunogenic compositions for pathogens other than mumps, gene therapy, and cell Stargeting.

0 This invention also relates to an isolated nucleic acid molecule comprising the consensus sequence of the complete genome or antigenome of Mumps virus, wherein it comprises the sequence of SEQ ID NO; 1 in the positive strand, antigenomic message.

This invention also relates to an isolated nucleic acid molecule encoding the complete genome or antigenome of Mumps virus, wherein it comprises a sequence in the positive strand, antigenomic message sense selected from the group consisting of SEQ ID NO: 11 and 12.

This invention also relates to the isolated nucleic acid of claim 2 in which one or more of the genes encoding the mumps virus proteins NP, P/I/V M, F, SH, HN and L may be variant proteins, wherein: each variant retains the function of the corresponding viral protein, (ii) the variant amino acid sequence has at least 70% overall identity to the original viral protein, and (iii) the nucleic acid sequence encoding the variant has at least 70% overall identity to the nucleic acid sequence encoding the original viral protein.

This invention also relates to a rescue composition for the recombinant production of mumps virus, which comprises a transcription vector, comprising a T7 polymerase gene and cDNA according to claim 10 placed between a T7 RNA polymerase promoter and a selfcleaving ribozyme sequence, and (ii) at least one expression vector which comprises polynucleotide sequences encoding the trans-acting proteins (NP, P and L) necessary for encapsidation, transcription and replication of Mumps virus.

The above-identified embodiments and additional embodiments, which are discussed in detail herein, represent aspects of this invention.

s:W\ntwLESu PnmWamaa mws w ao3 Page 7 oswocmea COMS ID No: ARCS-201170 Received by IP Australia: Time 16:31 Date 2008-08-06 .AUG-2008 16:36 PHILLIPS ORMOND NO. 617 P. 12 00 7a

CI

O

Brief Description of the Figures Figure 1 depicts a diagram showing the organization of the MUVCAT minireplicon DNA construct and T7 RNA polymerase-transcribed minireplicon antisense RNA genome.

Key restriction endonuclease sites utilized in the assembly of the DNA construct are shown.

The T7 RNA polymerase promoter sequence was designed to start transcription with the exact MUV 5' terminal nucleotide, and a HDV ribozyme sequence was positioned to generate the precise MUV 3' terminal nucleotide in minireplicon RNA transcripts. Duplicate T7 RNA polymerase termination signals were included in tandem after the HDV ribozyme sequence.

The CAT ORF replaces all of the coding and intercistronic sequence of the MUV genome; the remaining essential MUV specific sequence comprises the 3' MUV Leader (55 nt) with adjacent 90nt NP MWVsPittAs4V PqeA70032 Wys wa P2ac 7 COMS ID No: ARCS-201170 Received by IP Australia: Time 16:31 Date 2008-08-06 1 WO 01/09309 PCT/ITS00/2192 n 8 gene untranslated region (UTR), and the 5' MUV Trailer (24 nt) adjacent to the 137nt L gene UTR.

c Figure 2 is a schematic representation of the MUV full-length genome mt 5 cDNA construct, including the sub-genomic fragments and restriction O endonuclease sites used in the assembly process. The T7 RNA polymerase promoter and the HDV ribozyme sequence were positioned to initiate transcription with the exact 5' terminal nucleotide and generate the precise 3' terminal nucleotide of the MUV antisense genome, respectively. Tandem T7 RNA polymerase termination sequences were placed adjacent to the HDV ribozyme to help improve the efficiency of RNA cleavage. Nucleotide substitutions utilized as identifying tags for rescued MUV are shown at Table 1 (See Figure 8).

Figure 3A depicts three thin layer chromatograms that show CAT activity present in 293 cells following infection with MUV and transfection with RNA transcribed in vitro from pMUVCAT as described in Example 2.

Figure 3B depicts thin layer chromatograms showing CAT activity in MVA-T7 infected Hep2 and A549 cells following transfection with pMUVCAT and plasmids expressing MUV NP, P and L proteins. The level of pMUVNP expression plasmid was titrated in both cell lines; lanes 1-4 show CAT activity following transfection with mixtures containing 200ng pMUVCAT, pMUVP, 200ng pMUVL each, and 300ng, 450ng, 600ng, 750ng pMUVNP respectively; lane 5 shows CAT activity produced when pMUVL was omitted from the transfection mixture.

Figure 4 depicts the Passage (P1) of transfected cell supernatants on A549 cells, as described in Example 3. Views A, B and C correspond to ~I WO 01/09309 PCT/US00/21192 0 9 r rescued mumps virus, no mumps virus (control) and Jeryl Lynn strain of mumps. The views show similar infectious foci for A and C.

Figure 5 depicts a whole cell ELISA of rescued mumps virus on a Vero C 5 cell monolayer, as described in Example 3.

O

O Figure 6 shows the gel analysis of RT/PCR products used to identify rMUV (as described in Example Total RNA was prepared from Vero cell monolayers infected with passage 2 of rMUV virus from transfected cells.

RT/PCR reactions were set up to generate cDNA products spanning the 3 separate nucleotide tag sites present only in pMUVFL and rMUV. Lane 1 shows marker 1kb ladder (Gibco/BRL); lanes 2, 3 and 4 show RT/PCR products spanning nucleotide tag positions 6081, 8502 and 11731, respectively.

To demonstrate that these RT/PCR products were not derived from contaminating plasmid DNAs, an identical reaction to that used for the generation of the cDNA shown in lane 4 was performed without RT; the product(s) of this reaction are shown in lane 5. To demonstrate that no rMUV could be recovered when pMUVL was omitted from transfection mixtures, a RT/PCR reaction identical to that used to generate the cDNA products shown in lane 4 was set up using Vero cell RNA derived from transfections carried out without pMUVL; products from this reaction are shown in lane 6.

Figure 7 depicts three electropherograms B, and C) showing nucleotide sequence across identifying tag sites in rMUV. RT/PCR products (Figure which were sequenced across each of the three tag sites. The nucleotide sequence at each tag site obtained for rMUV cDNA is compared with consensus sequence for the plaque isolate of MUV (plaque isolate 4, PI 4) used to derive pMUVFL.

(cs WO 01/09309 PCT/US00/21192 1 Figure 8 is a table (Table 1) that lists the nucleotide and amino acid differences between the full length cDNA clone and the plaque isolate 4 (PI4) l^and the consensus sequence for the Jeryl Lynn strain (SEQ ID NO. 1).

tn 5 Figure 9 is a table (Table 2) which describes a complete gene map for 0 mumps virus, including the gene start and gene end for mumps virus proteins.

The sequence of the 55 nucleotide long 3' leader and 24 nucleotide long trailer are also shown.

Figure 10 is a table (Table 3) that lists the mumps virus gene transcription start and stop nucleotide positions, along with the translation start and stop positions for the individual genes of the mumps genome as provided in SEQ ID NO 1. The nucleotides from each transcription (gene) start and to each stop nucleotide position in Table 3 correspond to nucleotide sequences for proteins NP, P, M, F, SH, HN and L (SEQ ID NOS 93-99, respectively).

Figure 11 is a diagram showing the insertion of the luciferase and betagalactosidase gene(s) into the mumps virus genome between the M and the F genes. An AscI site was generated by site directed mutagenesis in the 5' noncoding region of the M gene. Nested PCR was used to generate mumps virus specific M-F intergenic sequence(s) and terminal AscI sites flanking each reporter gene. The resulting PCR product(s) were digested with AscI and imported into the genome AscI site.

Figure 12 is a diagram showing the insertion of two genes (luciferase and CAT) into the mumps virus genome. Two separate transcription units and a single transcription unit containing an internal ribosomal entry site for expression of the second gene of the polycistron, were separately inserted into the AscI site present in the M-F intergenic region. Nested PCR was used to WO 01/09309 PCT/US00/21192 O 11 I generate the appropriate mumps virus M-F intergenic sequence flanking each gene and transcriptional unit.

Figure 13 depicts the results from the MAPREC analysis of ten Mumpsvax® vaccine samples for relative portions of JL5/JL2 as determined from RNA was isolated from ten vials of mumps Jeryl Lynn vaccine and O amplified by RT-PCR, as described in Example 7. The tested samples in Lanes

C

I 1 and 2 are serial dilutions of undigested PCR product used to define the lower limits of linearity for the assay. In Lane 3 the PCR product is from a purified isolate of JL5. In Lane 4, the PCR product is from a purified isolate of JL2.

In Lanes 5-8, the PCR products are from samples of JL5 and JL2 viruses mixed in the following ratios: 99 JL5/ 1 JL2, 95 JL5/ 5 JL2, 85 JL5/ 15 JL2, and 25 JL2, respectively. For Lanes 9-18, the PCR products are from Mumpsvax® samples 1-10.

Figure 14 depicts a thin layer chromatogram that shows CAT activity present in the extracts of Vero cells which were infected with rMUV containing both the CAT and luciferase genes, as described in Example Figure 15 is a photograph showing cytological staining of Vero cell monolayers which were infected with rMUV containing the beta-galactosidase gene, as described n Example 5. The presence of intense blue stain indicated beta-galactosidase expression and activity. Panel C also shows a "clear" plaque made by rMUV which did not contain any additional foreign genes.

Brief Summary of Primary Sequences WO 01/09309 PCT/US00/21192 S12 Sequence 1 is the consensus nucleotide sequence for the full-length genome for Jeryl Lynn strain of mumps virus. (SEQ ID NO. which is written in the antigenomic 5' to message sense.

Sequence 2 is the amino acid sequence of the mumps virus Jeryl Lynn 0strain NP protein. (SEQ ID NO. 2) Sequence 3 is the amino acid sequence of the mumps virus Jeryl Lynn strain P protein. (SEQ ID NO 3) Sequence 4 is the amino acid sequence of the mumps virus Jeryl Lynn strain I protein. (SEQ ID NO 4) Sequence 5 is the amino acid sequence of the mumps virus Jeryl Lynn strain V protein. (SEQ ID NO Sequence 6 is the amino acid sequence of the mumps virus Jeryl Lynn strain M protein. (SEQ ID NO 6) Sequence 7 is the amino acid sequence of the mumps virus Jeryl Lynn strain F protein. (SEQ ID NO 7) Sequence 8 is the amino acid sequence of the mumps virus Jeryl Lynn strain SH protein. (SEQ ID NO 8) Sequence 9 is the amino acid sequence of the mumps virus Jeryl Lynn strain HN protein. (SEQ ID NO 9) Sequence 10 is the amino acid sequence of the mumps virus Jeryl Lynn strain L protein. (SEQ ID NO WO 01/09309 PCT/US00/21192 0 13 Sequence 11 is the complete nucleotide sequence of mumps Jeryl Lynn variant for plaque 2 (SEQ ID NO 11). Plaque 1 differed from plaque 2 at position 1703 (See Table Sequence is written as DNA in antigenomic 5' to sense.

Sequence 12 is the complete nucleotide sequence of mumps Jeryl Lynn JL2 variant for plaque 2 (SEQ ID NO 12). Plaque 1 differs from plaque 2 at nucleotide positions (See Table Sequence is written as DNA in antigenomic 5' to sense.

Detailed Description of the Invention As noted above, the present invention relates to a method of producing recombinant mumps virus (MUV). Such methods in the art are referred to as "rescue" or reverse genetics methods. Several rescue methods for different nonsegmented, negative-strand viruses are disclosed in the following referenced publications: Baron and Barrett, 1997; Collins et al., 1995; Garcin et al., 1995; He et al., 1997; Hoffman and Banerjee, 1997; Lawson et al., 1995; Radecke and Billeter, 1997; Radecke et al., 1995; Schneider et al., 1997; Schnell, 1994; Whelan et al., 1995. Additional publications on rescue include published International patent application WO 97/06270 for MV and other viruses of the subfamily Paramyxovirinae, and for RSV rescue, published International patent application WO 97/12032.

Before conducting rescue of recombinant mumps virus, it was necessary to develop a consensus sequence for the entire mumps virus (Jeryl Lynn strain) and also develop a minireplicon rescue system for mumps virus (MUV). The consensus sequence is obtained by sampling the population of RNA genomes N WO 01/09309 PCT/US00/21192 0 I14 present during a mumps virus infection of a cell. Correspondingly, further embodiments of this invention relate to an isolated polynucleotide sequence encoding the genome or antigenome of mumps virus or proteins thereof, as well C as variants of such sequences. Preferably, under high stringency conditions, In 5 these variant sequences hybridize to polynucleotides encoding one or more O mumps proteins (See Table 2 of Figure 9 for a complete map of the mumps virus, including the gene start and gene stop end for mumps virus proteins).

More preferably, under high stringency conditions, these variant sequences hybridize to polynucleotides encoding one or more mumps virus strains, such as the polynucleotide sequences of SEQ ID NOS. 1, 11 and 12. For the purposes of defining high stringency southern hybridization conditions, reference can conveniently be made to Sambrook et al. (1989) at pp. 387-389 which is herein incorporated by reference, where the washing step at paragraph 11 is considered high stringency. This invention also relates to conservative variants wherein the polynucleotide sequence differs from a reference sequence through a change to the third nucleotide of a nucleotide triplet. Preferably these conservative variants function as biological equivalents to the mumps virus reference polynucleotide reference sequence. The "isolated" sequences of the present invention are non-naturally occurring sequences. For example, these sequences can be isolated from their normal state within the genome of the virus; or the sequences may be synthetic, i.e. generated via recombinant techniques, such as well-known recombinant expression systems, or generated by a machine.

This invention also relates to nucleic acid molecules comprising one or more of such polynucleotides. As noted above, a given nucleotide consensus sequence may contain one or more of the genomes within the population of a mumps virus, such as the Jeryl Lynn strain. Specific embodiments employ the consensus nucleotide sequence of SEQ ID. NOS 1, 11 or 12, or nucleotide sequences, which when transcribed, express one or more of the mumps virus *t WO 01/09309 PCT/US00/21192

O

0 proteins (NP, P/I/V, M, F, SH, HN and See Table 3 of Figure 10 for the C71 gene start, translation start, translation end, and gene end for these mumps virus proteins.

Further embodiments relate to the amino acid sequences for the mumps ¢cr C virus proteins NP, P/I/V, M, F, SH, HN and L as set forth in SEQ ID NOS. 2respectively and also to fragments or variants thereof. Preferably, the C1 fragments and variant amino acid sequences and variant nucleotide sequences expressing mumps virus proteins are biological equivalents, i.e. they retain substantially the same function of the proteins in order to obtain the desired recombinant mumps virus, whether attenuated, infectious or both. Such variant amino acid sequences are encoded by polynucleotides sequences of this invention. Such variant amino acid sequences may have about 70% to about and preferably about 90%, overall similarity to the amino acid sequences of the mumps virus protein. The variant nucleotide sequences may have either about 70% to about 80%, and preferably about 90%, overall similarity to the nucleotide sequences which, when transcribed, encode the amino acid sequences of the mumps virus proteins or a variant amino acid sequence of the mumps virus proteins. Exemplary nucleotide sequences for mumps virus proteins NP, P/I/V, M F, SH, HN and L are described in Tables 1 and 2 (of Figures 8 and 9, respectively).

The biological equivalents can be obtained by generating variants of the nucleotide sequence or the protein sequence. The variants can be an insertion, substitution, deletion or rearrangement of the template sequence. Variants of a mumps polynucleotide sequence can be generated by conventional methods, such as PCR mutagenesis, amino acid (alanine) screening, and site specific mutagenesis. The phenotype of the variant can be assessed by conducting a rescue with the variant to assess whether the desired recombinant mumps virus WO 01/09309 PCT/US00/21192 S16 is obtained or the desired biological effect is obtained. The variants can also be assessed for antigenicity if the desired use is in an immunogenic composition.

c Amino acid changes may be obtained by changing the codons of the t 5 nucleotide sequences. It is known that such changes can be obtained based on 0 substituting certain amino acids for other amino acids in the amino acid sequence. For example, through substitution of alternative amino acids, small conformational changes may be conferred upon protein that may result in a reduced ability to bind or interact with other proteins of the mumps virus.

Additional changes may alter the level of attenuation of the recombinant mumps virus.

One can use the hydropathic index of amino acids in conferring interactive biological function on a polypeptide, as discussed by Kyte and Doolittle (1982), wherein it was found that certain amino acids may be substituted for other amino acids having similar hydropathic indices and still retain a similar biological activity. Alternatively, substitution of like amino acids may be made on the basis of hydrophilicity, particularly where the biological function desired in the polypeptide to be generated is intended for use in immunological embodiments. See, for example, U.S. Patent 4,554,101 (which is hereby incorporated herein by reference), which states that the greatest local average hydrophilicity of a "protein," as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity.

Accordingly, it is noted that substitutions can be made based on the hydrophilicity assigned to each amino acid.

In using either the hydrophilicity index or hydropathic index, which assigns values to each amino acid, it is preferred to introduce substitutions of WO 01/09309 PCTUSOO/21192 17 0 amino acids where these values are with +1 being particularly preferred, and those within 0.5 being the most preferred substitutions.

Preferable characteristics of the mumps virus proteins, encoded by the nucleotide sequences of this invention, include one or more of the following: being a membrane protein or being a protein directly associated with a membrane; capable of being separated as a protein using an SDS acrylamide C1 gel; and retaining its biological function in contributing to the rescue and production of the desired recombinant mumps virus in the presence of other appropriate mumps virus proteins.

With the above nucleotide and amino acid sequences in hand, one can then proceed in rescuing mumps virus. Mumps rescue is achieved by conducting transfection, or transformation, of at least one host cell, in media, using a rescue composition. The rescue composition comprises a transcription vector comprising an isolated nucleic acid molecule which comprises at least one polynucleotide sequence encoding a genome or antigenome of mumps virus and (ii) at least one expression vector which comprises one or more isolated nucleic acid molecule(s) encoding the transacting proteins necessary for encapsidation, transcription and replication; under conditions sufficient to permit the co-expression of said vectors and the production of the recombinant virus. By antigenome is meant an isolated positive message sense polynucleotide sequence which serves as the template for synthesis of progeny genome. Preferably, a polynucleotide sequence is a cDNA which is constructed to provide upon transcription a positive sense version of the mumps genome corresponding to the replicative intermediate RNA, or antigenome, in order to minimize the possibility of hybridizing with positive sense transcripts of complementing sequences encoding proteins necessary to generate a transcribing, replicating nucleocapsid. The transcription vector comprises an operably linked transcriptional unit

O

SWO 01/09309 PCT/USOO/21192 18 (In comprising an assembly of a genetic element or elements having a regulatory role in the mumps expression, for example, a promoter, a structural gene or coding sequence which is transcribed into mumps RNA, and appropriate transcription initiation and termination sequences.

I O The transcription vector is co-expressed with mumps virus proteins, NP, P and L, which are necessary to produce nucleocapsid capable of RNA replication, and also render progeny nucleocapsids competent for both RNA replication and transcription. The NP, P and L proteins are generated from one or more expression vectors plasmids) encoding the required proteins, although one, or one or more, of these required proteins may be produced within the selected host cell engineered to contain and express these virusspecific genes and gene products as stable transformants. In a preferred embodiment, NP, P and L proteins are expressed from an expression vector.

More preferably, NP, P and L proteins are each expressed from separate expression vectors, such as plasmids. In the latter instance, one can more easily control the relative amount of each protein that is provided during transfection, or transformation. Additional mumps virus proteins may be expressed from the plasmids that express for NP, P or L, or the additional proteins can be expressed by using additional plasmids.

Although the amount of NP, P and L will vary depending on the tolerance of the host cell for their expression, the plasmids expressing NP, P and L are adjusted to achieve an effective molar ratio of NP, P and L, within the cell. The effective molar ratio is a ratio of NP, P and L that is sufficient to provide for successful rescue of the desired recombinant mumps virus. These ratios can be obtained based on the ratios of the expression plasmids as observed in minireplicon (CAT/reporter) assays. In one embodiment, the molecular ratio of transfecting plasmids pMUVNP: pMUVP is at least about 16:1 and pMUVP:pMUVL is at least about about 1:6. Preferably, the WO 01/09309 PCT/US00/21192

O

O 19 0 Smolecular ratio of pMUVNP: pMUVP is about 16:1 to about 4:1 and pMUVP:pMUVL is about 1:6 to about 1:1. More preferably, the ratio of pMUVNP: pMUVP is about 6:1 to about 5:1 and pMUVP:pMUVL is about -1:3 to about 1:2.

r After transfection, or transformation, of a genomic cDNA plasmid along O with mumps virus expression plasmids pMUVNP, pMUVP and pMUVL, an

C

exact copy of genome RNA is produced by the combined action of phage T7 RNA polymerase and a vector-encoded ribozyme sequence that cleaves the RNA to form the 3' termini. This RNA is packaged and replicated by viral proteins initially supplied by co-transfected expression plasmids. In the case of the mumps virus rescue, a source that expresses T7 RNA polymerase is added to the host cell (or cell line), along with the source(s) for NP, P and L. Mumps rescue is achieved by co-transfecting this cell line with a mumps virus genomic cDNA clone containing an appropriately positioned T7 RNA polymerase promoter and expression plasmid(s) that encodes the mumps virus proteins NP, P and L.

For rescue of mumps, a cloned DNA equivalent of the desired viral genome is placed between a suitable DNA-dependent RNA polymerase promoter the T7 RNA polymerase promoter) and a self-cleaving ribozyme sequence the hepatitis delta ribozyme) which is inserted into a suitable transcription vector (e.g a bacterial plasmid). This transcription vector provides the readily manipulable DNA template from which the RNA polymerase T7 RNA polymerase) transcribes a single-stranded RNA copy of the viral antigenome (or genome) with the precise, or nearly precise, and 3' termini. The orientation of the viral genomic DNA copy and the flanking promoter and ribozyme sequences determines whether antigenome or genome RNA equivalents are transcribed.

I

WO 01/09309 PCT/US00/21192 In Accordingly, in the rescue method a rescue composition is employed.

The rescue composition can be varied as desired for a particular need or application. An example of a rescue composition is a composition which ¢C comprises a transcription vector comprising an isolated nucleic acid tn 5 molecule which comprises a polynucleotide sequence encoding a genome or 0 antigenome of mumps virus and (ii) at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins necessary for encapsidation, transcription and replication. The transcription and expression vectors are selected such that transfection of the rescue composition in a host cell results in the co-expression of these vectors and the production of the recombinant mumps virus.

As noted above, the isolated nucleic acid molecule comprises a sequence which encodes at least one genome or antigenome of a mumps virus. The isolated nucleic acid molecule may comprise a polynucleotide sequence which encodes a genome, antigenome or a modified version thereof. In one embodiment, the polynucleotide encodes an operably linked promoter, the desired genome or antigenome, a self-cleaving ribozyme sequence and a transcriptional terminator.

In a preferred embodiment of this invention, the polynucleotide encodes a genome or anti-genome that has been modified from a wild-type mumps virus by a nucleotide insertion, rearrangement, deletion or substitution. In preferred embodiments, the polynucleotide sequence encodes a cDNA clone for a recombinant mumps virus. It is submitted that the ability to obtain replicating virus from rescue may diminish as the polynucleotide encoding the native genome and antigenome is increasingly modified. The genome or antigenome sequence can be derived from that of any strain of mumps virus. The polynucleotide sequence may also encode a chimeric genome formed from WO 01/09309 PCT/US00/21192 0 21 n recombinantly joining a genome or antigenome or genes from one or more S* heterologous sources.

Since the recombinant viruses formed by the methods of this invention can be employed as tools in diagnostic research studies or as therapeutic or N1 prophylactic immunogenic compositions, the polynucleotide may also encode a O wild type or an attenuated form of the mumps virus selected. In many r1 embodiments, the polynucleotide encodes an attenuated, infectious form of the mumps virus. In particularly preferred embodiments, the polynucleotide encodes a genome or antigenome of a mumps virus having at least one attenuating mutation in the 3' genomic promoter region and having at least one attenuating mutation in the RNA polymerase gene, as described by published International patent application WO 98/13501, which is hereby incorporated by reference.

In addition to polynucleotide sequences encoding the modified forms of the desired mumps genome and antigenome as described above, the polynucleotide sequence may also encode the desired genome or antigenome along with one or more heterologous genes or a desired heterologous nucleotide sequence. These variants are prepared by introducing selected nucleotide sequences into a polynucleotide sequence encoding a genome or antigenome of mumps. Preferably, a desired heterologous sequence is inserted within an intergenic region of the mumps genome. However, the desired heterologous sequence can be inserted within a non-coding region of the mumps polynucleotide sequence, or inserted between a non-coding region and a coding region, or inserted at either end of the polynucleotide sequence. In alternative embodiments a desired heterologous sequence may be inserted within the coding region of a non-essential gene, or in place of the coding region for a non-essential gene. The insertion site choice can make use of the 3' to gradient of expression of mumps virus. The heterologous nucleotide sequence WO 01/09309 PCT/US00/21192 I22 gene) can vary as desired. Depending on the application of the desired recombinant virus, the heterologous nucleotide sequence may encode a cofactor, cytokine (such as an interleukin), a T-helper epitope, a restriction marker, adjuvant, or a protein of a different microbial pathogen virus, bacterium, fungus or parasite), especially proteins capable of eliciting a 0 Sprotective immune response. It may be desirable to select a heterologous sequence that encodes an immunogenic portion of a co-factor, cytokine (such as an interleukin), a T-helper epitope, a restriction marker, adjuvant, or a protein of a different microbial pathogen virus, bacterium or fungus) in order to maximize the likelihood of rescuing the desired mumps virus, or minireplicon virus vector. Other types of non-mumps moieties include, but are not limited to, those from cancer cells or tumor cells, allergens amyloid peptide, protein or other macromolecular components. For example, in certain embodiments, the heterologous genes encode cytokines, such as interleukin-12, which are selected to improve the prophylatic or therapeutic characteristics of the recombinant virus.

Examples of such cancer cells or tumor cells include, but are not limited to, prostate specific antigen, carcino-embryonic antigen, MUC-1, Her2, CA-125 and MAGE-3.

Examples of such allergens include, but are not limited to, those described in United States Patent Number 5,830,877 and published International Patent Application Number WO 99/51259, which are hereby incorporated by reference, and include pollen, insect venoms, animal dander, fungal spores and drugs (such as penicillin). Such components interfere with the production of IgE antibodies, a known cause of allergic reactions.

Amyloid peptide protein (APP) has been implicated in diseases referred to variously as Alzheimer's disease, amyloidosis or amyloidogenic 0 WO 01/09309 PCT/US00/21192

(N

0 23 r disease. The P-amyloid peptide (also referred to as AP peptide) is a 42 amino acid fragment of APP, which is generated by processing of APP by the P and y secretase enzymes, and has the following sequence: Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu SMet Val Gly Gly Val Val Ile Ala (SEQ ID NO 97).

In some patients, the amyloid deposit takes the form of an aggregated Ap peptide. Surprisingly, it has now been found that administration of isolated Ap peptide induces an immune response against the Ap peptide component of an amyloid deposit in a vertebrate host (See Published International Patent Application WO 99/27944). Such Ap peptides have also been linked to unrelated moieties. Thus, the heterologous nucleotides sequences of this invention include the expression of this Ap peptide, as well as fragments of AP peptide and antibodies to Ap peptide or fragments thereof.

One such fragment of Ap peptide is the 28 amino acid peptide having the following sequence (As disclosed in U.S. Patent 4,666,829): Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys (SEQ ID NO 98).

These heterologous sequences may be used in embodiments of this invention that relate to mumps virus vectors, which can be used to deliver varied RNAs, amino acid sequences, polypeptides and proteins to an animal or human. The examples set forth herein demonstrate the ability of mumps virus to express one or more heterologous genes (and even 3, 4, or 5 genes) under control of the mumps virus transcriptional promoter. In alternative embodiments, the additional heterologous nucleic acid sequence may be a single sequence of up to 7 to 10 kb, which is expressed as a single extra transcriptional unit. Preferably, the Rule of Six (Calain and Roux, 1993) is followed. In certain preferred embodiments this sequence may be up to 4 to 6 WO 01/09309 PCT/US00/21192 I 24 kb. One may also insert heterologous genetic information in the form of additional monocistronic transcriptional units, and polycistronic transcriptional units. Use of the additional monocistronic transcriptional units, and polycistronic transcriptional units should permit the insertion of more genetic information. In preferred embodiments, the heterologous nucleotide sequence Sis inserted within the mumps genome sequence as at least one polycistronic transcriptional unit, which may contain one or more ribosomal entry sites.

In alternatively preferred embodiments, the heterologous nucleotide sequence encodes a polyprotein and a sufficient number of proteases that cleaves said polyprotein to generate the individual polypeptides of the polyprotein.

The heterologous nucleotide sequence can be selected to make use of the normal route of infection of mumps virus, which enters the body through the respiratory tract and can infect a variety of tissues and cells, for example, salivary glands, lymphoid tissue, mammary glands, the testes and even brain cells. The heterologous gene may also be used to provide agents which are used for gene therapy or for the targeting of specific cells. As an alternative to merely taking advantage of the normal cells exposed during the normal route of mumps infection, the heterologous gene, or fragment, may encode another protein or amino acid sequence from a different pathogen which, when employed as part of the recombinant mumps virus, directs the recombinant mumps virus to cells or tissue which are not in the normal route of mumps virus. In this manner, the recombinant mumps virus becomes a vector for the delivery of a wider variety of foreign genes.

For embodiments employing attenuated mumps viruses, conventional means are used to introduce attenuating mutations to generate a modified virus, such as chemical mutagenesis during virus growth in cell cultures to which a chemical mutagen has been added, followed by selection of virus that has been subjected to passage at suboptimal temperature in order to select temperature

I

WO 01/09309 PCTUS00/21192 0 sensitive and/or cold adapted mutations, identification of mutant viruses that produce small plaques in cell culture, and passage through heterologous hosts to select for host range mutations. An alternative means of introducing attenuating mutations comprises making predetermined mutations using site- 5 directed mutagenesis. One or more mutations may be introduced. These I viruses are then screened for attenuation of their biological activity in cell

O

0culture and/or in an animal model. Attenuated mumps viruses are subjected to nucleotide sequencing to locate the sites of attenuating mutations.

A rescued recombinant mumps virus is tested for its desired phenotype (temperature sensitivity, cold adaptation, plaque morphology, and transcription and replication attenuation), first by in vitro means, such as sequence identification, confirmation of sequence tags, and antibody-based assays.

If the attenuated phenotype of the rescued virus is present, challenge experiments can be conducted with an appropriate animal model. Non-human primates provide the preferred animal model for the pathogenesis of human disease. These primates are first immunized with the attenuated, recombinantly-produced virus, then challenged with the wild-type form of the virus.

The choice of expression vector as well as the isolated nucleic acid molecule which encodes the trans-acting proteins necessary for encapsidation, transcription and replication can vary depending on the selection of the desired virus. The expression vectors are prepared in order to permit their coexpression with the transcription vector(s) in the host cell and the production of the recombinant virus under selected conditions.

A mumps rescue includes an appropriate cell milieu, preferably mammalian, in which T7 RNA polymerase is present to drive transcription of WO 01/09309 PCT/US00/21192 n26 the antigenomic (or genomic) single-stranded RNA from the viral genomic cDNA-containing transcription vector. Either co-transcriptionally or shortly thereafter, this viral antigenome (or genome) RNA transcript is encapsidated into functional templates by the nucleocapsid protein and engaged by the required polymerase components produced concurrently from co-transfected C expression plasmids encoding the required virus-specific trans-acting proteins.

These events and processes lead to the prerequisite transcription of viral mRNAs, the replication and amplification of new genomes and, thereby, the production of novel viral progeny, rescue.

In the rescue method of this invention, a T7 RNA polymerase can be provided by recombinant vaccinia virus. This system, however, requires that the rescued virus be separated from the vaccinia virus by physical or biochemical means or by repeated passaging in cells or tissues that are not a good host for vaccinia virus. This requirement is avoided by using as a host cell restricted strain of vaccinia virus MVA-T7) which does not proliferate in mammalian cells. Two recombinant MVAs expressing the bacteriophage T7 RNA polymerase have been reported. The MVA/T7 recombinant viruses contain one integrated copy of the T7 RNA polymerase under the regulation of either the 7.5K weak early/late promoter (Sutter et al., 1995) or the 11K strong late promoter (Wyatt et al., 1995).

The host cell, or cell line, that is employed in the transfection of the rescue composition can vary widely based on the conditions selected for rescue.

The host cells are cultured under conditions that permit the co-expression of the vectors of the rescue composition so as to produce the desired recombinant mumps virus. Such host cells can be selected from a wide variety of cells,.

including eukaryotic cells, and preferably vertebrate cells. Avian cells may be used, but preferred host cells are derived from a human cell, such as a human embryonic kidney cell. Exemplary host cells are human 293 cells, A549 cells WO 01/09309 PCT/US00/21192 0 27 Sand Hep2 cells. Vero cells as well as many other types of cells can also be used as host cells. Other examples of suitable host cells are: Human Diploid Primary Cell Lines: e.g. WI-38 and MRC5 cells; Monkey Diploid Cell Line: e.g. FRhL Fetal Rhesus Lung cells; Quasi-Primary Continuous Cr 5 Cell Line: e.g. AGMK -African green monkey kidney cells.; other potential I¢ cell lines, such as, CHO, MDCK (Madin-Darby Canine Kidney), and primary

O

0chick embryo fibroblasts (CEF). Some eukaryotic cell lines are more suitable than others for propagating viruses and some cell lines do not work at all for some viruses. A cell line is employed that yields detectable cytopathic effect in order that rescue of viable virus may be easily detected. In the case of mumps, the transfected cells can be co-cultured on Vero cells because the virus spreads rapidly on Vero cells and makes easily detectable plaques. In general, a host cell which is permissive for growth of the selected virus is employed.

In alternatively preferred embodiments, a transfection-facilitating reagent may be added to increase DNA uptake by cells. Many of these reagents are known in the art. LIPOFECTACE (Life Technologies, Gaithersburg, MD) and EFFECTENE (Qiagen, Valencia, CA) are common examples. Lipofectace and Effectene are both cationic lipids. They both coat DNA and enhance DNA uptake by cells. Lipofectace forms a liposome that surrounds the DNA while Effectene coats the DNA but does not form a liposome.

The transcription vector and expression vector can be plasmid vectors designed for expression in the host cell. The expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins necessary for encapsidation, transcription and replication may express these proteins from the same expression vector or at least two different vectors.

These vectors are generally known from the basic rescue methods, and they need not be altered for use in the improved methods of this invention.

_I

c WO 01/09309 PCT/USOO/21192 0 t 28 In the method of the present invention, a standard temperature range (about 32*C to about 37*C) for rescue can be employed; however, the rescue at an elevated temperature has been shown to improve recovery of the recombinant RNA virus. The elevated temperature is referred to as a heat Sshock temperature (See Published International Patent Application Number WO 99/63064, which is hereby incorporated herein by reference). An effective heat shock temperature is a temperature above the standard temperature suggested for performing rescue of a recombinant virus at which the level of recovery of recombinant virus is improved. An exemplary list of temperature ranges is as follows: from 38°C to about 47*C, with from about 42 0 C to about 46 0 C being the more preferred. Alternatively, it is noted that heat shock temperatures of 43 0 C, 44 0 C, and 45 0 C are particularly preferred.

Numerous means are employed to determine the level of recovery of the desired recombinant mumps virus. As noted in the examples herein, a chloramphenicol acetyl transferase (CAT) reporter gene is used to monitor and optimize conditions for rescue of the recombinant virus. The corresponding activity of the reporter gene establishes the baseline and test level of expression of the recombinant virus. Other methods include detecting the number of plaques of recombinant virus obtained and verifying production of the rescued virus by sequencing.

In preferred embodiments, the transfected rescue composition, as present in the host cell(s), is subjected to a plaque expansion step (i.e.

amplification step). The transfected rescue composition is transferred onto at least one layer of plaque expansion cells (PE cells). The recovery of recombinant virus from the transfected cells is improved by selecting a plaque expansion cell in which the mumps virus or the recombinant mumps virus exhibits enhanced growth. Preferably, the transfected cells containing the WO 01/09309 PCT/USOO/21192 0 29 I.C rescue composition are transferred onto a monolayer of substantially confluent PE cells. The various modifications for rescue techniques, including plaque expansion, are also set forth in Published International Patent Application Number WO 99/63064.

lt~ The recombinant mumps viruses prepared from the methods of the present invention are employed for diagnostic, prophylactic and therapeutic applications. Preferably, the recombinant viruses prepared from the methods of the present invention are attenuated. The attenuated recombinant virus should exhibit a substantial reduction of virulence compared to the wild-type virus which infects human and animal hosts. The extent of attenuation is such that symptoms of infection will not arise in most individuals, but the virus will retain sufficient replication competence to be infectious and elicit the desired immune response profile for vaccines. The attenuated recombinant virus can be used alone or in conjunction with pharmaceuticals, antigens, immunizing agents or adjuvants, as vaccines in the prevention or amelioration of disease. These active agents can be formulated and delivered by conventional means, i.e. by using a diluent or pharmaceutically acceptable carrier.

Accordingly, in further embodiments of this invention attenuated recombinantly produced mumps virus is employed in immunogenic compositions comprising at least one recombinantly produced attenuated mumps virus and (ii) at least one of a pharmaceutically acceptable buffer or diluent, adjuvant or carrier. Preferably, these compositions have therapeutic and prophylactic applications as immunogenic compositions in preventing and/or ameliorating mumps infection. In such applications, an immunologically effective amount of at least one attenuated recombinant mumps virus of this invention is employed in such amount to cause a substantial reduction in the course of the normal mumps infection.

WO 01/09309 PCT/US00/21192 The formulation of such immunogenic compositions is well known to t persons skilled in this field. Immunogenic compositions of the invention may comprise additional antigenic components polypeptide or fragment thereof or nucleic acid encoding an antigen or fragment thereof) and, preferably, include a pharmaceutically acceptable carrier. Suitable N pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The term "pharmaceutically acceptable carrier" refers to a carrier that does not cause an allergic reaction or other untoward effect in patients to whom it is administered. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antigen. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in immunogenic compositions of the present invention is contemplated.

Administration of such immunogenic compositions may be by any conventional effective form, such as intranasally, parenterally, orally, or topically applied to mucosal surface such as intranasal, oral, eye, lung, vaginal, or rectal surface, such as by aerosol spray. The preferred means of administration is parenteral or intranasal.

Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.

WO 01/09309 PCT/US00/21192 0 31 The vaccine compositions of the invention can include an adjuvant, including, but not limited to aluminum hydroxide; aluminum phosphate; Stimulon' QS-21 (Aquila Biopharmaceuticals, Inc., Framingham, MA); MPL" Cr 5 (3-O-deacylated monophosphoryl lipid A; RIBI ImmunoChem Research, ~Hamilton, MT), IL-12 (Genetics Institute, Cambridge, MA); N-acetyl-

O

Smuramyl--L-threonyl-D-isoglutamine (thr-MDP); N-acetyl-nor-muramyl-Lalanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); Nacetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-( '-2'-dipalmitoyl-snglycero-3-hydroxyphos-phoryloxy)-ethylamine (CGP 19835A, referred to a MTP-PE); and cholera toxin. Others which may be used are non-toxic derivatives of cholera toxin, including its B subunit (for example, wherein glutamic acid at amino acid position 29 is replaced by another amino acid, preferably, a histidine in accordance with Published International Patent Application WO 00/18434, which is hereby incorporated herein), and/or conjugates or genetically engineered fusions of non-mumps polypeptides with cholera toxin or its B subunit, procholeragenoid, fungal polysaccharides.

The recombinantly produced attenuated mumps virus of the present invention may be administered as the sole active immunogen in an immunogenic composition. Alternatively, however, the immunogenic composition may include other active immunogens, including other immunologically active antigens against other pathogenic species. The other immunologically active antigens may be replicating agents or non-replicating agents. Replicating agents include, for example, attenuated forms of measles virus, rubella virus, variscella zoster virus (VZV), Parainfluenza virus (PIV), and Respiratory Syncytial virus (RSV).

One of the important aspects of this invention relates to a method of inducing immune responses in a mammal comprising the step of providing to WO 01/09309 PCT/US00/21192 0 tI 32 said mammal an immunogenic composition of this invention. The immunogenic composition is a composition which is immunogenic in the treated animal or human such that the immunologically effective amount of the Spolypeptide(s) contained in such composition brings about the desired response against mumps infection. Preferred embodiments relate to a method for the Ctreatment, including amelioration, or prevention of mumps infection in a human comprising administering to a human an immunologically effective amount of the immunogenic composition. The dosage amount can vary depending upon specific conditions of the individual. This amount can be determined in routine trials by means known to those skilled in the art.

Certainly, the isolated amino acid sequences for the proteins of the mumps virus may be used in forming subunit vaccines. They may also be used as antigens for raising polyclonal or monoclonal antibodies and in immunoassays for the detection of anti-mumps virus protein-reactive antibodies.

Immunoassays encompassed by the present invention include, but are not limited to those described in U.S. Patent No. 4,367,110 (double monoclonal antibody sandwich assay) and U.S. Patent No. 4,452,901 (western blot), which U.S. Patents are incorporated herein by reference. Other assays include immunoprecipitation of labeled ligands and immunocytochemistry, both in vitro and in vivo.

This invention also provides for a method of diagnosing a mumps infection, or identifying a mumps vaccine strain that has been administered, comprising the step of determining the presence, in a sample, of an amino acid sequence of SEQ ID NOS 2-10. Any conventional diagnostic method may be used. These diagnostic methods can easily be based on the presence of an amino acid sequence or polypeptide. Preferably, such a diagnostic method matches for a polypeptide having at least 10, and preferably at least 20, amino acids which are common to the amino acid sequences of this invention.

WO 01/09309 PCTIUS00/21192 0 33 The nucleic acid sequences disclosed herein can also be used for a variety of diagnostic applications. These nucleic acids sequences can be used to prepare relatively short DNA and RNA sequences that have the ability to C' 5 specifically hybridize to the nucleic acid sequences encoding the mumps virus Sproteins. Nucleic acid probes are selected for the desired length in view of the selected parameters of specificity of the diagnostic assay. The probes can be used in diagnostic assays for detecting the presence of pathogenic organisms, or in identifying a mumps vaccine that has been administered, in a given sample.

With current advanced technologies for recombinant expression, nucleic acid sequences can be inserted into an expression construct for the purpose of screening the corresponding oligopeptides and polypeptides for reactivity with existing antibodies or for the ability to generate diagnostic or therapeutic reagents. Suitable expression control sequences and host cell/cloning vehicle combinations are well known in the art, and are described by way of example, in Sambrook et al. (1989).

In preferred embodiments, the nucleic acid sequences employed for hybridization studies or assays include sequences that are complementary to a nucleotide stretch of at least about 10 to about 20 nucleotides, although at least about 10 to 30, or about 30 to 60 nucleotides can be used. A variety of known hybridization techniques and systems can be employed for practice of the hybridization aspects of this invention, including diagnostic assays such as those described in Falkow et al., US Patent 4,358,535.

In general, it is envisioned that the hybridization probes described herein will be useful both as reagents in solution hybridizations as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) from suspected clinical samples, such as exudates, body fluids amniotic fluid, middle ear effusion, WO 01/09309 PCT/US00/21192 0 z 34 bronchoalveolar lavage fluid) or even tissues, is absorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired C conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required (depending, for example, on the G+C C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe, Following washing of the hybridized surface so as to remove nonspecifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label.

The nucleic acid sequences which encode the mumps virus proteins of the invention, or their variants, may be useful in conjunction with PCR T M technology, as set out, in U.S. Patent 4,603,102. One may utilize various portions of any of mumps virus sequences of this invention as oligonucleotide probes for the PCR T amplification of a defined portion of a mumps virus gene, or mumps virus nucleotide, which sequence may then be detected by hybridization with a hybridization probe containing a complementary sequence.

In this manner, extremely small concentrations of mumps nucleic acid may be detected in a sample utilizing the nucleotide sequences of this invention.

The following examples are included to illustrate certain embodiments of the invention. However, those of skill in the art should, in the light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

The following examples are provided by way of illustration, and should not be construed as limitative of the invention as described hereinabove.

I I WO 01/09309 PCTUS00/21192 0 t EXAMPLES Example 1 MATERIALS AND METHODS c ICells and viruses. Primary chick embryo fibroblast (CEF) cells were

O

Sobtained from SPAFAS Inc., Preston, CT), and cultured in Eagle's Basal Medium (BME) supplemented with 5% fetal calf serum. Hep 2 cells, 293 cells, A549, and Vero cells were obtained from the American Type Culture Collection (ATCC) and grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum. The Jeryl Lynn strain of mumps virus was cultured directly on CEF cells from a vial of Mumpsvax®, Lot Numbers 0089E, 0656J, and 1159H (Merck and Co., Inc., West Point, PA). Recombinant vaccinia virus Ankara (MVA-T7), expressing bacteriophage T7 RNA polymerase was obtained from Dr. B. Moss [(National Institutes of Health, Bethesda, MD), see Wyatt et al., 1995].

l.A. Generation of mumps virus Jeryl Lynn consensus sequence.

Growth of mumps virus Jeryl Lynn strain stock. Mumps virus Jeryl Lynn strain was cultured directly from vials of Mumpsvax (lot 1159H, Merck and Co., Inc.) on primary chick embryo fibroblasts (CEFs, Spafas, Inc.) in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% fetal calf serum or in Eagle's Basal Medium (BME) supplemented with 5% fetal calf serum. CEFs plated on T-75 flasks were infected with resuspended Mumpsvax at an approximate multiplicity of infection (moi) of 0.002 for 2 hours at room temperature. The inoculum was removed from the cells and replaced with fresh media. Cells were incubated at 37*C for 4 days, at which time extensive syncytia and cytopathology was observed. Virus was collected by scraping the cells into the culture media, followed by freeze-thawing twice in a dry ice/ WO 01/09309 PCTfUSOO/21192 36 ethanol bath followed by incubation at 37C. Cell debris was removed by centrifugation at 2,500 rpm in a Beckman GS-6KR centrifuge (Beckman Instruments, Inc., Palo Alto, CA). Virus was stored at Isolation of viral RNA, amplification, and sequencing.

Mumps viral RNA was isolated from frozen aliquots of virus using Trizol LS Reagent according to the manufacturer (GibcoBRL, Grand Island, NY). Reverse transcription followed by polymerase chain reaction (RT- PCR) was performed using the isolated viral RNA as a template and using the Titan One -Tube RT-PCR System (Boehringer Mannheim, Indiananpolis, IN).

The mumps genome was amplified in four separate fragments, using the following primer pairs: 1 ACCAAGGGGAGAATGAATATGGG23 (SEQ ID NO. 95) and 3

S

7

CTGAACTGCTCTACTAATCTGGAC

3 ,(SEQ I1D NO. 82) (3.9 kb product); 3 mCTGTG]TACA FfCrrATCTGTGACAG 3 (SEQ ID NO. 21) and 778TGTAACTAGGATCTGATTCCAAGC776 (SEQ ID NO. 72) (4 kb product); 767 AGAGTAGATCAGCGTGCTTTGAG-no (SEQ DD NO. 32) and l 1 u 5

CCTGGATCTGTTTTCTTCTACCG

1 62 (SEQ ID NO. 62) (4 kb product); 11529

GTGTTAATCCCATGCTCCGTGGAG

1 552 (SEQ ID NO. 42) and 15 3 4ACCAAGGGGAGAAAGTAAAATC 1 5 m (SEQ ID NO. 53) (3.9 kb product). The suggested protocol from the manufacturer (Boehringer Mannheimn, Indiananpolis, IN, catalog 1855476) was followed for the RT and PCR conditions. The PCR products were purified on a 1 agarose gel.

WO 01/09309 PCT/US00/21192 0 37 SThe PCR products were sequenced using an Applied Biosystems (ABI) 377 Sequencer (Applied Biosystems, Inc., Foster City, CA). For sequencing purposes, a series of primers was designed which spanned the entire mumps genome as shown in Table 4 below. These primer sequences were based on Cr 5 nucleotide sequence information obtained from Genbank for a varying t combination of incompletely sequenced mumps virus strains. Using the 0published sequences, a hypothetical mumps genome sequence was devised encoding its proteins and then the primers were generated therefrom, In order to determine properly the sequences at the 5' and 3' ends of the mumps virus Jeryl Lynn genome, viral genome RNA was ligated at its ends and cDNA was then amplified by PCR across the ligated region. For each reaction, viral RNA was incubated in 10% DMSO, 5X ligation buffer and deionized water at 83*C for 3 minutes to denature any secondary structures, and then placed immediately on ice. T4 RNA ligase (20 Units, New England Biolabs, Inc., Beverly, MA) and 40 Units of RNasin (Promega) were added to give a final ligation mixture of 20 pl which was incubated overnight at 16"C.

The ligation products were phenol/chloroform-extracted and subjected to RT- PCR using the following primer pair which spanned the ligated region of the genome: 5 ,6GCGCATTGATATTGACAATGs,, 5 (SEQ ID NO. 52) and 2

,,CCCTCCTCACCCCTGTCTTG

1 (SEQ ID NO. 92) The PCR products were subjected to a second round of PCR using the following nested primers: ,2, 7

GAATAAAGACTCTTCTGGC,,

52 (SEQ ID NO. 93) and ,3GGTAGTGTCAAAATGCCCCC,,, (SEQ ID NO. 94). The final PCR products were gel-purified and sequenced.

Table 4 WO 01/09309 WO 0109309PCTIUSOOI21192 Primers for sequencing MUV genome I ACCAAGGGGAGAATGAATATGGG (SEQ ID NO: 38 CTCAGCAGGCATGCAAAATCmx (SEQ ID NO: 96) 7 6,CAAGATACATGCTGCAGCCG 7 84 (SEQ ED NO: 13) 11 9GTCCTAGATGTCCAAATGCG I18a (SEQ ED NO: 14) 15oGACT1AGAGCACAGCC1TJ2 1 m (SEQ ID NO: 184,CAATCTAGCCACAGCTAACTis~i (SEQ ED NO: 16) 21 7 CGTTGCACCAGTACTCA1TG 2126 (SEQ ID NO: 17) 2484

GGCATAGACGGGAATGGAGC

5

M

3 (SEQ ID NO: 18) 3mTITCGAGCAACGATTGGCAAAGGC m (SEQ ID NO: 19) 3712 CCAGCTCCGATAAATATGTCyn, (SEQ ID NO: 3 m3CTGTGTrACATrC1TATCTGTGACAG 37 9, (SEQ ID NO: 21) 4w ~CTGACAGTCAGCATAGGAGA4., (SEQ ID NO: 22) 4 M4GAAGTCTGCCTCAATGAGAA 43 ,3 (SEQ ID NO: 23) 4 16

CCAACCCACTGATAACAGCT

4 3 5 (SEQ ID NO: 24) 1 $CCAGCATTGTCACCGATTAG S204 (SEQ ID NO: SSISCAATACAATGAGGCAGAGAG,.4 (SEQ ID NO: 26) 6m TGAATCTCCTAGGGTCGTAACGTC624 (SEQ ID NO: 27) 5952 GAGCAACCATCAGCTCCAAT 59 7 (SEQ- ID NO: 28) 633 oCATACCCTGTATGTCTGGAC635 (SEQ ID NO: 29) 67 3 GGATGATCAATGATCAAGGC68m (SEQ ID NO: 71 2GGTAAGACACACTGGTGCTA 7 9 1 (SEQ ED NO: 31) 7 67 AGAGTTrAGATCAGCGTGCTTrTGAG -no, (SEQ ED NO: 32) 7 u7GCTGGTGGCCGTATGAACTCC., (SEQ ID NO: 33) 1 naCAGATGACCATCACUTGAG .3 (SEQ ID NO: 34) mm CCTAGTCTCCGGTGGACCCG 867 (SEQ ID NO: 91 6CACTGATATGTTAGAGGGAC 918 (SEQ ID NO: 36) 958CCGAGAGTCCATGTGTGCTC m (SEQ ID NO: 37) locoo AGAGGATGACAGATTCGATC 10 19 (SEQ ID NO: 38) 1 0 41 GAGATAGCAGCCTGCTTCTzo,3 (SEQ ID NO: 39) 1081 3 GCTCAGTCATT'CCGAGAAGA10932 (SEQ ID NO: 11,I3GTCAGGACATCACTAATjCT 1 2 2 (SEQ ID NO: 41) 11GTGTITAATCCCATGCTCCGTGGAG 1 552 (SEQ* ID NO: 42) 12MGCAGTAGTGGTGATGACAAG,2. (SEQ ID NO: 43) 123 75

CTCCTATGCATCTCTAGCT

1 23, (SEQ ID NO: 44) 1279GCAGATGGTAAATAGCATCA 21 2 (SEQ ID NO: 32 9 CGATATGAGATAGTTG-rC 1323 (SEQ ID NO: 46) 1 3mGTCATCCGAATCAGCATCC 13 4 2 (SEQ ED NO: 47) 4m6CAAGCAGGTATAGCAGCAGG,4.

5 (SEQ ID NO: 48) 143u8CCGACCCGAATAATCACGAG,44 (SEQ ID NO: 49) 14775 CATCAGATCATGACACCCTA,479 (SEQ ID NO: 1 4 63GTGATAACACCCATGGAGATTC 14 93 (SEQ ID NO: 51) 15166WGGCATTGATATTGACAATG (SEQ ED NO: 52) WO 01/09309 WO 0109309PCTUJS00I21192 134ACCAAGGGGAGAAAGTAAAATC156 1 4 9n CATGGGTGTTATCACGTCTC 4958 1 4549 CAACACGCCTCCTCCAGTAC 4530 1 4 2olGTACACCCTCCAGATCCACA 14182 jm7CCATGATGTGGATGATAAAC 37 n ,34 2 CATATrCGACAGnTGGAGT 33 93 MRI CAAGGTCATATACACATAGT 3m 1MCTACACAAGACTCGACAGGT123j3 1, 9 7 CTCCCGCTAATCTGAGTCtT 12178 1,6mCCTTGGATCTGTTTTCTTCTACCG 1166 3 82CAGATATCTAGACAGTCCAGC 1 363 :1 0 1 7 GACATTGCCACGTCT ogg 06 10 GGGTAGQATCTGATGGAGGA 1059 1 01 2CGACCTGTAGCCT'ITATCTC 01 03 9753TCATGCCGCATCTCAATGAG r 93 m CACCATACTGTAATTGGGCG 93 37 .9.ACCCACTCCACTCATTGTTGAACC 8 w am TCAGCTCGAATTGCCTTCC 88 WGAGTATCTCATTTAGGCCCG U 2 773TGTAACTAGGATCTGATTCCAAGC 76 nGACAAGAAATGCACTCTGTA M7 735CATCACTGAGATATITGGATCm .99GATACCGTrACTCCGTGAAT 6 6 m 7 CAGACATACAGflATGATGAG 3 oz 57 53 GTGACTGCATGATGGTCAGG 5T3 3 s2 CATCTGCATCTCATCTAGCA 5333 49,CACGTGCATTCGTCTGTGCT 4932 45 8 GAAAAGATTGCATAGCCCAAGC 4 _w 4 2MCTGGAGAATAGCACTGGCAG 4237

W,

7 5 CTGAACTGCTCTTrACTAATCTGGAC 38 31 3530 GCACCCTGTCACTACAGGAG 3, 31 58 GTGAGTrCATATGGCGCTC 3 39 27 7GCTAGTGTTGTC=rACTGT 24 .TGAGGCTCCATrCCCGTCTATG 2 4 234GTTGGTI'GGATAGTTGGATC 2,, 1 7 80 GCCCACTTGCGACTGTGCGT 176 1 1 039 GGATCGGAGCTAGTGAGTr,102 6GTACACTGTAACACCGATCC 6 7 216 CCCTCTCACCCTGTCTTG,9 (SEQ ID NO: 53) (SEQ ID NO: 54) (SEQ ID NO: (SEQ ID NO: 56) (SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59) (SEQ ID NO: (SEQ ID NO: 61) (SEQ ID NO: 62) (SEQ ID NO: 63) (SEQ ID NO: 64) (SEQ ID NO: (SEQ ID NO: 66) (SEQ ID NO: 67) (SEQ ID NO: 68) (SEQ ID NO: 69) (SEQ ID NO: (SEQ ID NO: 71) (SEQ ID NO: 72) (SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: (SEQ ID NO: 76) (SEQ ID NO: 77) (SEQ ID NO: 78) (SEQ ID NO: 79) (SEQ ID NO: (SEQ ID NO: 81) (SEQ ID NO: 82) (SEQ ID NO: 83) (SEQ ID NO: 84) (SEQ ID NO: (SEQ ID NO: 86) (SEQ ID NO: 87) (SEQ ID NO: 88) (SEQ ID NO: 89) (SEQ ID NO: (SEQ ID NO: 91) (SEQ ID NO:92)

I

O

O

WO 01/09309 PCT/US00/21192 040 z n Prior work had shown that the Jeryl Lynn vaccine strain contained a mixture of two distinct virus populations (Afzal et al., 1993). Therefore in order to minimize the potential for sub-optimal protein-protein interactions (by C splicing together cDNA fragments derived from the different virus populations 0 5 into the genome cDNA during the rescue process, a well isolated plaque from C the Jeryl Lynn vaccine preparation (designated as plaque isolate 4, PI 4) was selected and amplified for the derivation of the full length genome cDNA, and the NP, P and L expression plasmids.

1.B Construction of expression plasmids for MUV NP, P and L proteins. Expression plasmids for the MUV NP, P and L proteins (pMUVNP, pMUVP, pMUVL) were constructed by splicing cDNA for each ORF between the T7 RNA polymerase promoter and the T7 RNA polymerase transcription termination sequence of a modified plasmid vector pEMC (Moss et al., 1990) which contained the cap independent translation enhancer (CITE) of encephalomyocarditis virus (EMC). The primers used for RT-PCR amplification of the MUV NP protein ORF, from total MUV infected-cell (CEF) RNA, were CGTCTC CCATGTTGTCTGTGCTCAAAGC (SEQ ID NO 99) and ATCATTCTCGAG TTGCGATTGGGGTTAGTTTG (SEQ ID NO 100); the resulting cDNA fragment was gel purified, trimmed with BsmBI and XhoI,and then ligated into NcoI/XhoI cut pEMC, such that the AUG of the NP protein ORF was adjacent to the CITE. Primers for the amplification of the MUV P ORF were 5' TTCCGGGCAAGCCATGGATC (SEQ ID NO 101) and ATCATTCTC GAGAGGGAATCATTGTGGCTCTC (SEQ ID NO 102). The P ORF cDNA (modified by site-directed mutagenesis to include the two G nucleotides which are co-transcriptionally inserted by viral polymerase to generate P mRNA) was also cloned into the NcoI/XhoI sites of pEMC. Because of it's large size the L protein ORF was assembled in two steps; primers ATCATTCGTCTCCCATGGCGGGCCTAAATGAGATACTC (SEQ ID NO 103) and 5' CTTCGTTCA TCTGTTTTGGATCCG (SEQ ID NO 104) were 7-- SWO 01/09309 PCT/US00/21192 0 41 used in the first step to produce a cDNA fragment which was trimmed with BsmBI and BamHI, then cloned into the NcoI/BamHI sites of pEMC. In the second step primers 5' CAGAGT ACCTTATATCGGATCC (SEQ ID NO 105) and 5' ATCATTCTGCAGGAATTTGGAT GTTAGTTCGGCAC (SEQ ID NO C 5 106) were used to amplify a cDNA fragment which was cloned into the In BamHI/PstI sites of the plasmid from step one above, to complete the L protein SORF. Four cDNA clones for each of the three ORFs were sequenced and the ORF with the highest level of homology to the Jeryl Lynn consensus nucleotide/amino acid sequence was chosen in each case for use in rescue experiments.

1.C. Construction of a synthetic MUV minireplicon. Referring to Figure 1, The T7 RNA polymerase promoter sequence was designed to start transcription with the exact MUV 5' terminal nucleotide, and a HDV ribozyme sequence (Been et al.) was positioned to generate the precise MUV 3' terminal nucleotide in minireplicon RNA transcripts. Duplicate T7 RNA polymerase termination signals were included after the HDV ribozyme sequence. The bacterial chloramphenicol acetyl transferase (CAT) ORF replaces all of the coding and intercistronic sequence of the MUV genome; the remaining essential MUV specific sequence comprises the 3' MUV Leader (55nt) with adjacent NP gene untranslated region (UTR), and the 5' MUV Trailer (24nt) adjacent to the 137nt L gene UTR.

The synthetic MUV minireplicon (MUVCAT) was assembled from cDNA representing a modified MUV genome, where all the coding and intercistronic regions were replaced by the CAT ORF. The cDNA for the MUV 3' and 5' ends was amplified by RT/PCR from total infected-cell (CEF) RNA, using primer pairs 5' ACCAAGGGGAGAATGAATATGGG (SEQ ID NO 107)/ 5'ATCATTCGTCTCTTTTCCAGGTAGTGTCAAAATGCC (SEQ ID NO 108), and 5'ACCAAGGGGAGAA AGTAAAATC (SEQ ID NO 109)/

I

WO 01/09309 PCT/US00/21192 42 ATCATTCGTCTCTATCGAATAAAGACTCTTCTGGC (SEQ ID NO 110) respectively. In a second round of PCR amplification nested primers were used for addition of the T7 RNA polymerase promoter and the 5' to NarI portion of the hepatitis delta virus (HDV) ribozyme sequence to the MUV 5' and 3' ends respectively; these primer pairs were: TACGACTCACTATAACCAAGGGGAGAAAGTAAAATC (SEQ ID NO 111)/ 5' ATCATT CGTCTCTATCGAATAAAGACTCTTCTGGC (SEQ ID NO 112); for addition of the T7 RNA polymerase promoter, and

ATCATTGGCGCCAGCGAGGAGGCTGGGACCATGCCGGCCACCAAGG

GGAGAATGAATATGGG (SEQ ID NO 113)/ ATCATTCGTCTCTTTCCAGGTAGTGTCAAAATGCC (SEQ ID NO 114) for addition of the ribozyme component. The CAT ORF cDNA was amplified using primers 5' TCATTCGTCTCGGAAAATGGAGAAAAAAAT CACTGGATATACC (SEQ ID NO 115) and 5'ATCATTCGTCTCTCGATTTA CGCCCCGCCCTGCCACTC (SEQ ID NO 116). All three components were gel purified, trimmed with BsmBI joined together in a four-way ligation and cloned into the Notl/NarI sites of modified pBSK S (+)(Sidhu et al., 1995) to produce the complete minireplicon plasmid, pMUVCAT.

1.D Construction of a full length genome cDNA for MUV. The full length genome cDNA of MUV (pMUVFL) was assembled 5' end to 3' end by the successive cloning of contiguous cDNA fragments into the same plasmid backbone that was used for the construction of pMUVCAT (See Figure Each cDNA fragment was amplified from total infected-cell RNA by RT- PCR using primer pairs which contained suitably unique restriction sites; in each case the positive sense primer contained a 5' proximal Nod site in addition to the virus specific endonuclease site, to facilitate the step-wise cloning strategy. Prior to addition to the growing full length clone, the cDNA fragment spanning the virus 3' end to the BssHII site was assembled separately WO 01/09309 PCT/US00/21192 0 43 tj in pBluescript II (Stratagene, La Jolla, CA). In the first step the BssHII/ClaI cDNA fragment was cloned into the ClaI/XhoI sites of pBluescript, using a 5' extended primer to generate an XhoI site adjacent to the virus specific BssHII site. In the second step the virus 3' end to Clal cDNA fragment c 5 was cloned into the NotI/ClaI sites of plasmid from the first step to complete Sthe virus 3' end to BssHl sequence: The T7 RNA polymerase promoter O sequence was added to the virus 3' end by incorporation into the sense RT/PCR primer used to generate the virus 3'end/ClaI terminal fragment. The terminal fragment (BamHI/NarI) of the genome cDNA was separately modified in a second round of PCR amplification in order to add the 5'end to Narl portion of the HDV ribozyme sequence. A total of four cloning cycles was employed for assembly of pMUVFL; after each round, four clones were sequenced in the region of newly added cDNA and compared to MUV consensus sequence. The cDNA clone containing the least number of mutations was then selected for addition of the next cDNA fragment. The fully assembled cDNA clone was resequenced to verify stability during bacterial amplification.

Electrocompetent SURE cells (Stratagene, La Jolla, CA) and DH5alpha cells (GibcoBRL, Grand Island, NY) were used as bacterial hosts for cloning of MUV cDNA.

1.E Rescue of CAT activity from transfected cells. For rescue of CAT activity, cells were either infected with MUV and transfected with in vitro transcribed MUVCAT minireplicon RNA or infected with MVA-T7 and transfected with pMUVCAT along with pMUVNP, pMUVP and pMUVL expression plasmids. In vitro transcriptions were carried out with 4 pg of pMUVCAT as the template for T7 RNA polymerase in a 20/l final volume according to the manufacturer's protocol (Promega, Madison, WI); template DNA was then digested with RQ-1 DNase. Overnight cultures of 293 cells grown to approximately 80% confluence in six-well dishes were infected with MUV at a moi of 1-2; at Ihour post infection (hpi) a mixture containing 5-1Ol WO 01/09309 PCT/US00/21192 0 44 of in vitro transcription reaction (approximately 5-10/g RNA) and 10-12pl of LipofectACE (GibcoBRL) was added to each well, according to the manufactuer's protocol. At 48hpi cells were scraped into suspension, collected Sby centrifugation, resuspended in 100,l of 0.25M tris buffer pH 7.8, and subjected to three rounds of freeze-thaw. The clarified cell extracts were then c assayed for CAT activity using either 4 C labelled chloramphenicol (Sidhu et al., 1995) or fluorescein labelled chloramphenicol as substrate (Molecular Probes. Eugene, Ore), followed by analysis of reaction products on a Thin Layer Chromatogram.

For rescue of CAT activity in the absence of MUV helper virus, 293, Hep2 and A549 cells were grown overnight in six-well dishes to approximately confluence, infected with MVA-T7 at an moi of 10 and transfected Ihpi with a mixture containing 200ng pMUVCAT, 300ng pMUVNP, pMUVP, 200ng pMUVL, and 10-12/i of LipofectACE. At 24hpi the transfection mixture was replaced with 2ml of fresh growth medium and cells were incubated for a further 24hr, followed by preparation of cell extracts and CAT assay as described above.

1.F Recovery of infectious full length MUV from transfected cells. For rescue of infectious MUV from cDNA, A549 cells grown overnight to approximately 90% confluence in six-well dishes were infected with MVA- T7 at an moi of 4; at lhpi cells were transfected with a mixture containing 3- 7ug pMUVFL, 300ng pMUVNP, 50ng pMUVP, 200ng pMUVL and 14l of Lipofectace. At 24hpi the transfection mixture was replaced with growth medium (DMEM containing 10% fetal calf serum), and cells were incubated at 37*C for a further 48hr; either supernatants (P1) or total transfected cell monolayers scraped into suspension were then transferred directly onto confluent A549 cell monolayers, which were incubated at 37°C for four days and then prepared for whole cell ELISA (see below) in order to detect MUV I I WO 01/09309 PCT/US00/21192 0 I infectious foci. Supernatants (P2) from these A549 indicator cells were further passaged onto confluent Vero cell monolayers and incubated at 37*C for 3-4 days to observe MUV induced syncytia.

l.G Identification and authentication of rescued MUV. Initial r identification of rescued MUV (rMUV) was carried out using a whole cell SELISA; A549 cells infected with transfection supernatants (see above) were

C

1 fixed with 10% formaldehyde in IX phosphate buffered saline (PBS) for at room temperature; cells were then rinsed once with PBS and once with blocking solution milk in xl PBS), followed by incubation overnight at 4"C in blocking solution. The overnight blocking solution was then removed and cells were incubated at room temperature for 2-3hr with MUV polyclonal rabbit antiserum (Access Biomedical, San Diego) diluted 1/400 in fresh blocking solution. The polyclonal antiserum was then removed; cells were rinsed 5X with blocking solution and were then incubated at room temperature for 2-3hr with horseradish peroxidase (HRP) conjugated goat anti-rabbit serum (DAKO Corporation, Carpinteria, CA), diluted 1/1000 in blocking solution.

The goat serum was then removed; cells were washed 5X with blocking solution and IX with PBS, followed by addition of enough AEC substrate (DAKO Corporation) to cover cell monolayers, which were then incubated at 37 0 C for 15-20mins to facilitate stain development.

Nucleotide tags present only in pMUVFL (not present in any laboratory grown Jeryl Lynn MUV) were verified in rMUV by sequence analysis of cDNA fragments amplified by RT/PCR from Vero cells infected with (P2) rMUV. RNA was prepared from infected cells in a six-well dish by extraction with Trizol (GibcoBRL) according to the manufacturer's protocol; one-fifth of the total RNA from each well was used as the template for RT/PCR amplification according to directions for the Titan Kit (Boehringer Mannheim, Indianapolis, IN), with primer pairs flanking each of three separate nucleotide i WO 01/09309 PCT/US00/21192 in 46 tags. The resulting RT/PCR fragments were purified from a 1% agarose gel by electroelution, and sequenced using an Applied Biosystems (ABI) 377 Ssequencer (Applied Biosystems, Inc., Foster City, CA) according to the r n manufacturer's protocols.

Example 2 Rescue of reporter gene activity from transfected cells. In order to help define a system which would permit the rescue of infectious mumps virus from cDNA, a mumps virus minireplicon containing the CAT reporter gene was assembled. The construct was designed to allow synthesis of a RNA minigenome of negative polarity under control of the T7RNA polymerase promoter. The three terminal G residues of the T7 promoter were omitted during construction of the minireplicon in order to provide a transcriptional start site which began with the precise 5' nucleotide of the MUV genome.

Inclusion of the HDV ribozyme in the minireplicon construct permitted cleavage of the T7RNA polymerase transcript to produce the authentic MUV specific 3' end. The total number of nucleotides (966) in the MUVCAT minireplicon RNA was divisible by six, in agreement with the Rule of Six (Calain and Roux, 1993), which states that unless the genome length is a multiple of six, efficient replication will not occur. Expression of the CAT gene was under control of a MUV specific promoter, and could occur only if minireplicon RNA became encapsidated with NP protein and then interacted with functional MUV specific RNA polymerase proteins.

Recovery of CAT activity was observed here using two different rescue systems. In the first procedure in vitro transcribed MUVCAT RNA was transfected into 293 cells which had been previously infected with MUV.

Under these conditions rescued CAT activity was usually relatively low, but was reproducible and always well above background levels (See Figure 3A).

Panels Al, A2 and A3 show the results from three separate rescue experiments; I WO 01/09309 PCTUS00/21192 0 47 r panel Al, lane 1 shows CAT activity in MUV-infected cells transfected without in vitro transcribed pMUVCAT RNA lane 2 shows CAT activity in MUV-infected cells transfected with RNA transcribed in vitro from pMUVCAT; lane 3 shows CAT activity in MUV-infected cells transfected with c 5 RNA transcribed in vitro from pMUVCAT-GG; lane 4 shows CAT activity in uninfected cells transfected with RNA transcribed in vitro from pMUVCAT.

O

SEach CAT assay shown in panel Al was carried out at 37"C for 3-4hrs with of the extract from approximately 106 transfected cells. Panel A2 lane 1 shows MUV-infected cells transfected with RNA transcribed in vitro from pMUVCAT; lane 2 shows uninfected cells transfected with RNA transcribed in vitro from pMUVCAT. Each CAT assay shown in panel A2 was carried out at 37*C for 5hrs using 50% of the extract from approximately 106 transfected cells. Panel A3 lane 1 shows MUV infected cells transfected with RNA transcribed in vitro from pMUVCAT; lane 2 shows MUV-infected cells transfected without in vitro transcribed pMUVCAT RNA; lane 3 shows uninfected cells transfected with in vitro transcribed RNA from pMUVCAT.

Each CAT assay shown in panel A3 was carried out at 37*C for 4hrs using of the extract from approximately 106 transfected cells.

CAT activity could not be rescued from a MUVCAT construct (pMUVCAT-GG) which contained 2 of the 3 additional G residues normally present in the T7RNA polymerase promoter. However, two mutations present in the MUV trailer region of the same MUVCAT construct prevented conclusive interpretation of this observation. Results from these experiments indicated that ntl-145 and nt15223-15384 of the MUV genome contained the necessary sequences for genome encapsidation, transcription and presumably replication. Having defined a minireplicon sequence which permitted rescue of CAT activity in the presence of MUV expressed helper proteins, a second system was designed to carry out rescue of CAT activity from transfected DNA, including pMUVCAT, pMUVNP, pMUVP and pMUVL. In this system I

I

SWO 01/09309 PCT/US00/21192 0 m 48 MUV NP, P and L proteins and MUVCAT minireplicon RNA transcripts were co-expressed inside 293, Hep2, and A549 cells, under control of MVA-T7 induced T7RNA polymerase. Initial experiments carried out in 293 cells indicated that CAT rescue was efficient and reproducible. Increased efficiency of CAT rescue was seen in Hep2 cells relative to 293 cells, and a series of Splasmid titrations was performed to optimize the relative amounts of each plasmid in the transfection mixture. Further increase in rescue efficiency was observed in A549 cells relative to Hep2 cells, with almost 100% conversion of substrate in a 3hr CAT assay, using 20% of A549 cell lysate from one well of a six well dish. (Fig3B). These results demonstrated that the MUV helper proteins expressed from pMUVNP, pMUVP and pMUVL were sufficient to promote encapsidation, replication and transcription of MUVCAT antisense RNA minigenomes. Furthermore, the optimal conditions observed for CAT rescue provided a starting point for the rescue of infectious MUV entirely from cDNA.

Example 3 Recovery of full length mumps virus from transfected cells. The full length MUV cDNA was assembled in such a way as to permit the synthesis of a precise 15,384nt positive sense RNA copy of the virus genome under control of the T7 RNA polymerase promoter. As with the MUVCAT minireplicon, the T7 RNA polymerase promoter sequence was modified to omit the three terminal G residues, providing a transcriptional start site beginning at the exact MUV terminal nucleotide. The HDV ribozyme was employed to generate the exact MUV 3' terminal nucleotide of the positive sense genome transcripts.

To recover MUV from cDNA, A549 cells were infected with MVA-T7 which expresses T7 RNA polymerase, and then transfected with pMUVFL, and plasmids expressing the MUV NP, P and L proteins. Results for rescue of reporter gene activity from the MUVCAT minireplicon along with results from

I

WO 01/09309 PCT/US00/21192 S49 similar work on the related rubulavirus SV5 (He et al, 1997; Murphy and Parks, 1997) indicated that the MUV NP, P and L proteins would be sufficient to encapsidate, replicate and then transcribe the T7 RNA polymerase generated positive sense genome RNA transcripts, provided all the interacting components 5 were present at operable levels and ratios. A549 cells were chosen for MUV Q rescue experiments because they supported MUV replication and more Sefficient CAT rescue activity than other cell lines tested (potentially through more efficient transfection), and they were also more resistant to MVA-T7 induced cytopathology. In the first successful rescue experiment, supernatant medium (without clarification) from transfected cells was transferred to fresh A549 indicator cells. Three infectious foci were observed by whole cell ELISA in one out of five wells of indicator cells (Figure Following passage of supernatant from these cells onto a fresh Vero cell monolayer three syncytia were observed under the microscope. One of these syncytia was aspirated into medium as a liquid plaque pick, and used to infect fresh Vero cells; numerous syncytia were then observed on this cell monolayer (Figure and total infected-cell RNA was extracted for identification of rescued virus. Ina second rescue experiment at least 10-20 infectious foci were obtained from each well of transfected cells as seen on indicator cells stained by whole cell ELISA (Figure In this experiment all wells, except where pMUVL was omitted from the transfection mixture, contained rescued virus, indicating that the rescue process was very reproducible. The optimal level of each plasmid so far determined for the rescue of MUV from cDNA is 300ng pMUVNP, 50ng pMUVP, 200ng pMUVL and 3-7p/g of pMUVFL.

Example 4 Identification of rescued MUV. It was important to demonstrate that rMUV was derived from pMUVFL. This was made possible by the presence of three nucleotide tags in pMUVFL, introduced by RT/PCR mis-incorporation I WO 01/09309 PCT/IUS00/21192

O

during assembly of the full length genome cDNA. These tags differentiated SpMUVFL from both the consensus sequences of the Jeryl Lynn vaccine virus, and a passaged plaque isolate of the Jeryl Lynn vaccine preparation from which C pMUVFL was derived. Two of the tags represented silent changes at O 5 nucleotides 6081 and 11731 in the F and L genes respectively; a third tag NC resulted in a Lys to Arg substitution at amino acid 22 of the L protein (corresponding to nucleotide position 8502) of pMUVFL. To show that rMUV was generated from pMUVFL and not from either of the other two MUV populations grown in the laboratory, RT/PCR products, prepared from rMUV infected-cell RNA, spanning each of the three nucleotide tags were sequenced at the relevant position(s). To demonstrate that these RT/PCR products were derived solely from infected cell RNA, and not from carry-over of trace quantities of transfecting plasmid DNA, one reaction was carried out with rMUV infected cell RNA as the template for PCR amplification without prior reverse transcription. Results from the RT/PCR amplifications, and subsequent sequencing analysis of RT/PCR products are shown in Figure 6. Total RNA was prepared from Vero cell monolayers infected with P2 rMUV virus from transfected cells. RT/PCR reactions were set up to generate cDNA products spanning the 3 separate nucleotide tag sites present only in pMUVFL and rMUV. Lane 1 shows marker 1kb ladder (Gibco/BRL); lanes 2,3 and 4 show RT/PCR products spanning nucleotide tag positions 6081, 8502 and 11731 respectively. To demonstrate these RT/PCR products were not derived from contaminating plasmid DNAs, an identical reaction to that used for the generation of the cDNA shown in lane 4 was performed without RT; the product(s) of this reaction are shown in lane 5. To demonstrate that no rMUV could be recovered when pMUVL was omitted from transfection mixtures, a RT/PCR reaction identical to that used to generate the cDNA products shown in lane 4 was set up using Vero cell RNA derived from transfections carried out without pMUVL; products from this reaction are shown in lane 6.

m r-- WO 01/09309 PCT/US00/21192 0 51 SThe consensus sequence data generated from the RT/PCR products shown in Figure 6 clearly demonstrate that the rescued MUV contained the same nucleotide tags present only in the full length genome cDNA of MUV (Figure See Table 1 of Figure 8 for a listing of the nucleotide and amino C 5 acid differences between the full length cDNA clone and the plaque isolate 4 V (PI 4) and the consensus sequence for Jeryl Lynn strain (SEQ ID NO 1).

O

In view of the above examples, it is concluded that infectious mumps virus has been produced from a DNA copy of the virus genome. This procedure required the co-transfection of MVA-T7-infected A549 cells with plasmids encoding MUV NP, P and L proteins, along with a plasmid containing the complete genome cDNA of mumps virus. The success of this process was contingent upon the development of a consensus sequence for the entire mumps virus genome (Jeryl Lynn strain) and the novel development of a mumps virus minireplicon rescue system.

Note: A Lys to Arg substitution at amino acid 22 of the L protein in the full length construct did not disrupt obtaining the rescued mumps virus.

Example Mumps Virus as an Expression Vector for One or More Heterologous Genes The following experiments establish mumps virus as an expression vector. This embodiment is demonstrated by the recovery of infectious recombinant mumps virus expressing one or more reporter genes.

I

WO 01/09309 PCT/US00/21192 S52 Construction of recombinant mumps virus that contain either the Beta-Galactosidase gene, the Firefly Luciferase gene, or the Firefly Luciferase gene and the CAT gene. In order to permit insertion of S heterologous genes or foreign genetic information into the mumps virus genome, a unique AscI restriction endonuclease site was generated in the full length genome cDNA, using site directed mutagenesis. The AscI site was positioned in the 5' non-coding region of the M gene (genome nucleotides 4451-4458), such that additional heterologous genes containing the appropriate flanking regulatory sequences of mumps virus and terminal Ascl sites, could be integrated into the mumps genome between the virus M and F genes, to produce novel infectious mumps virus recombinant(s) capable of expressing the foreign gene(s). Mumps virus recombinants containing either the betagalactosidase gene or the firefly luciferase gene have been constructed (see Figure 11). Another recombinant mumps virus containing the EMC virus CITE adjacent to the luciferase translation initiation codon was also constructed for comparison with protein (luciferase) levels produced by the luciferasecontaining recombinant which utilized the normal mumps virus cis-acting regulatory elements for initiation of translation.

The firefly luciferase gene was prepared for insertion into the mumps virus genome by two rounds of nested PCR, using primers which incorporated mumps virus specific sequences (genome nucleotides 4459-4538 and 4392-4449 respectively) adjacent to the ATG and UAA of the luciferase gene. In this.

process genome nucleotide 4450 was deleted from the PCR-generated DNA fragment to maintain the rule-of-six" in the final luciferase-containing recombinant genome; also, in the same DNA fragment, genome nucleotides 4539-4545 were replaced by the seven nucleotides normally found upstream of the luciferase ATG. Terminal AscI sites present in the final PCR product facilitated addition of the luciferase gene and flanking mumps virus specific sequence into the mumps virus genome. Similarly, a separate mumps virus I) WO 01/09309 PCT/US00/21192 0 53 Itr recombinant containing the beta-galactosidase gene was constructed. The PCRgenerated DNA fragment incorporating the beta-galactosidase gene and flanking mumps virus specific sequences contained the same deletion of genome Snucleotide 4450, as in the luciferase-containing DNA fragment. However a second TAA trinucleotide was incorporated adjacent to the normal TAA In translation termination codon of the-Beta-galactosidase gene, in order to Spreserve the "rule-of-six" in the final recombinant mumps virus genome. Also, C unlike the luciferase-containing construct the seven upstream nucleotides flanking the Beta-galactosidase ATG (genome nucleotides 4539-4545) were mumps virus specific. A third mumps virus recombinant containing the EMC virus CITE adjacent to the ATG of the luciferase gene, was also constructed.

As for the recombinant containing only the luciferase gene, nested PCR reactions were used to separately add mumps virus specific sequence at the end and 3' end of the CITE and luciferase gene, respectively. In a three way ligation, the 3' end of the CITE and the 5' end of the luciferase gene were joined at the Ncol restriction endonuclease site and added into the AscI site of the mumps virus genome. Genome nucleotide 4450 was deleted, and the trinucleotide ACT was added to the 5' end of the CITE during PCR in order to preserve the "rule-of-six" in the resulting recombinant mumps virus.

Mumps virus recombinants were constructed that contained both.the CAT gene and the luciferase gene, either as two separate transcriptional units, or as a single transcriptional unit containing the EMC CITE as an internal ribosomal entry site for translation of the second gene (luciferase) of the polycistron (see Figure 12). Nested PCR was used to generate two DNA fragments, one containing the CAT gene and the other the luciferase gene, each flanked with the appropriate mumps virus specific intergenic cDNA sequence.

Both of these fragments were joined and then ligated into the mumps virus genome cDNA via the AscI site previously used for the insertion of single reporter genes. Similarly, nested PCR was used to separately generate DNA I WO 01/09309 PCT/US00/211 i92

O

54 fragments containing the CAT gene and the EMC CITE fused to the luciferase gene, each flanked with appropriate mumps virus specific intergenic cDNA sequence. Both DNA fragments were joined and ligated into the Ascl site of the C mumps virus genome cDNA. The order of reporter genes in both genome constructs was 5' CAT-LUC 3' and 5' CAT CITE LUC 3' Rescue of mumps virus recombinants. Plasmids containing the recombinant mumps virus genomes, along with support plasmids expressing the mumps virus NP, P and L proteins were transfected into MVA-T7-infected A549 cells, as previously described above in Example 3. Total rescued virus from transfected cells was amplified first in fresh A549 cells (Passagel), and subsequently in Vero cells. At Passage 3, rescued virus was assayed for reporter gene activity.

Assay of reporter gene activity. Reporter gene activity was measured either in extracts of cells which had been infected with mumps. virus recombinants or by cytological staining of infected cell monolayers. Extracts from cells infected with mumps virus recombinants containing either the luciferase gene, or the luciferase gene fused to the EMC virus CITE were assayed for luciferase activity in a luminomiter (Analytical Luminescence Laboratory, Monolight 2010). The preparation of cell extracts and luciferase assays were performed according to the manufacturer's protocol for the Enhanced Luciferase Assay Kit (Pharmingen, San Diego, CA). Extracts from cells infected with mumps virus recombinants containing the beta-galactosidase gene were assayed by cytological staining according to the protocol for the beta-gal staining kit (Promega, Madison, Wise.). Measurement of CAT activity was carried out on freeze-thaw lysates of infected cells, as previously described in the above Examples.

WO 01/09309 PCT/US00/21192 0 Vtf Expression of Firefly luciferase by mumps virus. Robust luciferase activity was detected in the extracts of cells which had been infected with rescued virus. In each case, the rescued virus was derived from recombinant mumps virus genomic cDNAs which contained either the firefly luciferase gene 5 alone or both the CAT gene and the luciferase gene in tandem. See Figure 14, l which is a thin layer chromatogram that shows CAT activity present in the 0extracts of Vero cells which were infected with rMUV containing both the CAT and luciferase genes. Recombinant virus containing the CAT and luciferase genes as one transcriptional unit (rMUVC/C/L) were plaque purified (IX) from total rescued virus prior to CAT assay. Rescued recombinant virus containing the CAT and luciferase genes as individual transcription units (rMUVC/L) was assayed as a total population without plaque purification. Where indicated in Figure 14, luciferase activity in Vero cell extracts was also measured for both rMUVC/C/L and rMUVC/L virus recombinants.

In addition, Table 5 below shows the relative light units (RLU) readouts for clonal populations of mumps virus recombinants containing the luciferase gene (rMUV LUC and rMUV CITE-LUC), that were isolated from rescued virus populations by three successive rounds of plaque purification. The robust expression of luciferase activity by mumps virus recombinants, as shown in Table 5, clearly demonstrates the potential for mumps virus to express one or more heterologous genes from a recombinant genome(s).

Table 5. Quantitation of Luciferase produced by rMUVLUC and rMUVCITE-LUC I _I SWO 01/09309 PCT/US00/21192 0 56 rMUVCITE- 0.9 x Ios 6.7pg 190ng LUC-1 SrMUVCITE- 0.2 x 3.2pg 180ng LUC-2 rMUVCITE- 1.1 x 7.7pg 190ng LUC-4_ O RMUV 0 0 0 0 Average of two monolayer infections normalized to 10' input pfu.

Expression of beta-galactosidase by mumps virus. Rescued mumps virus containing beta-galactosidase has been identified. Rescued virus was derived from recombinant mumps virus genomic cDNA containing the betagalactosidase gene. Beta-galactosidase activity was evident in cells infected by recombinant mumps virus, following direct cytological staining. The intense blue stain of the beta-galactosidase activity was present only in cells infected by recombinant mumps virus which contained the beta-galactosidase gene.

Rescued mumps virus which did not contain any additional heterologous genes produced clear plaques in the same staining assay (see Figure 15). The expression of beta-galactosidase activity by recombinant mumps virus further demonstrates the ability of mumps virus to express relatively large heterologous genes under control of the mumps virus transcriptional promoter.

Example 6 Determination of the consensus sequence for JL5 and JL2 The Jeryl Lynn vaccine strain of mumps virus has been shown to consist of two individual variants, JL5 and JL2 (Afzal et al., 1993). The two variants, called JL5 and JL2, were shown to exist in a ratio of about 1 JL2 to 5 JL5 in the vaccine preparation. Since these variants possess sequence differences in the genome near the SH and HN genes, this difference was used to distinguish

I

t 0 WO 01/09309 PCT/USOO/21192 0 57 r the variants on the genetic level by isolating pure populations of each and sequencing their entire genomes.

Isolation of JL5 and JL2 variants from mumps virus Jeryl Lynn strain.

If) Mumps virus Jeryl Lynn strain was cultured directly on chick embryo 0 fibroblasts (CEFs) for one passage. This virus stock was then serially diluted in 10-fold increments and used to infect confluent CEFs on 6-well plates (Becton Dickinson, Franklin Lakes, NJ). Cells were infected by rocking at room temperature for 1 hours. The inoculum on each well was then replaced with an agarose overlay (containing 0.9% agarose [Seaplaque, FMC Bioproducts, Rockland, ME], minimal essential media [MEM], 0.2mM nonessential amino acids, 0.2 mg/ml penicillin/streptomycin, 2% FBS, and 0.3375% sodium bicarbonate). After the overlays solidified at room temperature, the infected cells were incubated at 37*C for 6 to 8 days until plaques were visible by eye and light microscopy.

Individual plaques containing viruses were isolated using sterile Pasteur pipettes (VWR Scientific, New York, NY) to remove an agarose plug over each plaque. The isolated plaques were placed in Iml of media (MEM supplemented with 2% FBS, 20 mM HEPES, and 0.1 mg/ml penicillin/streptomycin), vortexed, and used to infect for a second round of plaque purification. For subsequent steps, 10, 50, 75, 100, or 200 pl of each diluted plaque was used to infect fresh cells on 6-well plates. Infections, overlays, and plaque isolation were performed as described above. After isolating virus from the second round of plaquing, the process was repeated a third time.

Viruses isolated from third-round plaques were propagated on CEFs on 6-well plates for 4 to 6 days at 37C to prepare stocks. Viruses were then I

I

c WO 01/09309 PCT/US00/21192 0 58 expanded by.propagation on CEFs in T-25 flasks. After 5 to 7 days, when the infected cells showed the greatest cytopathology, viruses were harvested and stored frozen at C-i RT-PCR and sequencing of isolated variants.

RNA isolation and RT-PCR were performed as described in the "Isolation of viral RNA, amplification, and sequencing" section of example 1.A. The following gene-specific primers were used to amplify portions of the SH and HN genes: smTGAATCTCCTAGGGTCGTAACGTC,6 (SEQ ID NO 27) and 8sACCCACTCCACTCATTGTTGAACC 8 (SEQ ID NO 69).

Amplified products were gel-purified on 1% agarose and isolated from the gel slices using the Wizard PCR Purification Kit (Promega, Madison, WI).

Amplified products were then sequenced in the SH gene region [using primers amTGAATCTCCTAGGGTCGTAACGTC, (SEQ ID NO 27, 67 oGGATGATCAATGATCAAGGC (SEQ ID NO 732CATCACTGAGATATTGGATC76 (SEQ ID NO 74), oGATACCGTTACTCCGTGAATso (SEQ ID NO 75)] to identify them as or JL2.

Preliminary sequence analysis in the SH gene region was performed to define which purified viruses were JL5 and which were JL2. Initially, all triple-plaque-purified viruses matched JLS. To obtain JL2 isolates, viruses that had been plaque-purified once and stored frozen were screened by RT-PCR and sequencing in the SH gene region to determine whether they were JL2 or Two isolates identified in this manner as JL2-containing plaques were subjected to two additional consecutive rounds of plaque purification. As above, these isolates were expanded twice in CEFs followed by RNA extraction, amplification, and sequencing.

I WO 01/09309 PCTIUS00/21192 0 59 After defining each plaque isolate as either JL5 or JL2, two separate isolates of each variant were chosen for sequencing the entire genome. RT- PCR was performed on isolated RNA using the following primer pairs to amplify fragments spanning the entire genome: ,ACCAAGGGGAGAATGAATATGGGn (SEQ ID NO 95) and 2wTGAGGCTCCATTCCCGTCTATG24 (SEQ ID NO 86), 21 0 7CGTTGCACCAGTACTCATTG 2 1 2 6 (SEQ ID NO 17) and 3 7 5

CTGAACTGCTCTTACTAATCTGGAC

3 8 1 (SEQ ID NO 82), 3

VCTGTGTTACATCTTATCTGTGACAG

37 (SEQ ID NO 21) and 4, 7

CAGACATACAGGGTTATGATGAG

632 (SEQ ID NO 76), mTGAATCTCCTAGGGTCGTAACGTC6246 (SEQ ID NO 27) and gACCCACTCCACTCATTGTTGAACCm (SEQ ID NO 69), 7 ,,AGAGTTAGATCAGCGTGCTTTGAGo, (SEQ ID NO 32) and ,73TCATGCCGCATCTCAATGAG74 (SEQ ID NO 67), 9,5CCGAGAGTCCATGTGTGCTC6 (SEQ ID NO 37) and 6 8 ,CCTTGGATCTGTTTCTTCTACCG,662 (SEQ ID NO 62), 5 29GTGTTAATCCCATGCTCCGTGGAG,, 52 (SEQ ID NO 42) and 34 ,CATATTCGACAGTTTGGAGT,33, (SEQ ID NO 58), ,32,,CGATTATGAGATAGTGTTC,,3 (SEQ ID NO 46) and 1,,ACCAAGGGGAGAAAGTAAAATC, 5 3 (SEQ ID NO 53). Amplified products were purified and sequenced as described in the "Isolation of viral RNA, amplification, and sequencing" section of example 1.A. To determine the sequences of the genomic termini of each virus isolate, the RNA termini were ligated, followed by RT-PCR across the junction, and sequencing (as described in Example 1.A).

Sequences were aligned using Sequencher software (Genecodes, Ann Arbor, MI). The JLS and JL2 sequences represent the consensus determined 4 WO 01/09309 PCT/US00/21192

O

n by comparing both sequenced plaque isolates for each variant. Purified and JL2 viruses were sequenced with the same series of primers as listed in Table 4 of Example 1.A. For both variants, two separate plaque isolates were sequenced entirely (See SEQ ID NOS 11 and 12 for respective consensus I 5 sequences for JL5 and JL2, plaque 2 for each. As expected, a few sequence N differences were observed between the two JL5 plaque isolates (See table 6) and the two JL2 plaque isolates (See Table The consensus sequences of plaques 1 and 2 differed from Jeryl Lynn consensus sequence by 4 and 3 nucleotides, respectively (See Table 6).

The sequence of JL2 contains 413 differences from JL5, spread across the entire genome, as summarized in Table 8. Five of these differences are present in the viral 5' or 3' leader sequences. A total of 360 sequence differences lie within the coding regions of the viral genes; however, only 73 of these differences encode amino acid differences. The remaining 48 sequence differences lie within the noncoding regions of the viral genes. It is of interest to note that there are no sequence differences in the intergenic regions or within any of the internal cis-acting signals gene start or gene end signals).

Table 6. Sequence differences between plaque isolates for Position Jeryl Lynn JL5 JL5 Amino acid Gene/ Consensus Plaque 1 Plaque 2 AA position 1405 G A A pro (silent) N/ 420 1685 T C C tyr(T) or his(C) N/ 514 1703 T A T ser(T) or thr(A) N/ 520 9619 T C C phe (silent) L/ 394 Table 7. Sequence differences between plaque isolates for JL2.

Position Jeryl Lynn JL2 JL2 amino acid gene/ AA SConsensus Plaque 1 Plaque 2 position WO 01/09309 PCTUSOOI2 1192 4 A C A NA leader 3352 A C A gln(A) or his M/ 3508 T T C val(T) or ala(C) M/ 82 3517 T T C val(T or ala(C) M/ 13467 A G A lys(A) or arg(G) L/ 1677 I 1 WO 01/09309 PCT/US00/21192 62 Table 8. Summary of sequence differences between JL5 and JL2 variants.

Gene Differences between JL5 and JL2 noncoding region Coding silent 3' end 5' end Leader 4 Na na NP 3 9 8 P 2 2 14 22 M 2 1 5 17 F 2 6 12 33 SH 1 6 5 HN 4 3 16 L 0 7 13 145 Trailer 1 Na na TOTALS: 18 35 73 287 na not applicable.

Example 7 Determination of relative abundance of JL5 and JL2 in the Jeryl Lynn vaccine.

In order to determine the relative ratios of JL5 to JL2 in a vaccine lot of Jeryl Lynn, an assay was developed that exploited sequence differences due to a restriction endonuclease polymorphism between the two variants. The assay is called mutational analysis by PCR and restriction endonuclease cleavage (MAPREC). At position 3828 (antigenomic sense), there is a BssH II restriction endonuclease recognition site in the JL5 genome.

In JL2, a G to A nucleotide variation at this site results in a lack of BssH II recognition. RNA from a mixed population of JL5 and JL2 was isolated and amplified using primers surrounding this site, resulting in a 254 base pair product. The primers used were primers 3 7 o0CAGGCCAGCGCCGATAAATATG379 (SEQ ID NO 117) and 392AATGACACCCTTCTCCATCAGGG34, (SEQ ID NO 118). The primers SWO 01/09309 PCT/IUSOO/21192 0 63 z contained identical sequences to both JL5 and JL2; thus, the fragments from either variant were expected to amplify at equal probability. Furthermore, the Sfirst primer listed above contained fluorescein at its 5' end. The r^fluoresceinated fragment was cleaved with BssH II, and separated on an 5 acrylamide gel. A Fluorlmager was used to scan the gel and to quantitate the in") relative abundance of cleaved and uncleaved products, which represent JL5 and 0JL2, respectively. Cleavage with BssH II left a 120-base pair fluorescent product for JL5 and a 254-base pair uncleaved) fluorescent product for JL2.

RNA was isolated from ten vaccine vials of mumps virus Jeryl Lynn (Mumpsvax lot 0656J, Merck and Co., Inc., West Point, PA). The RNA was amplified (by using the above primers) and the PCR products were digested with BssH II, separated on a gel, and scanned on the Fluorlmager.

The enzyme digestion was performed by adding 5 units of BssH II (Roche Molecular Biology, Indianapolis, IN) to one-fifth of the PCR reaction mix and incubating at 50°C for 2 1/2 hours. The cleaved products were then separated on a 6 acrylamide gel that was then scanned using a Fluorlmager (Molecular Dynamics, Sunnyvale, CA).

Scanned images were quantitated using ImageQuapnt software (Molecular Dynamics, Sunnyvale, CA). A series of controls were used as standards; these samples consisted of pure JL5 and JL2 viruses mixed in the following ratios based on titers: 99% JL5/1% JL2, 95% JL5/ 5% JL2, 85% JL5/ 15% JL2, and 75% JL5/ 25% JL2. RNA was isolated from the mixed viruses and used in the MAPREC procedure. Results from these controls were used to generate a standard curve for the assay, which was used to determine the relative percentages of JL5 and JL2 in the vaccine mixtures. In addition, a series of two-fold dilutions of undigested JL5 PCR product was used to determine the linear range of the results measured on the Fluorlmager. Furthermore, pure

O

SWO 01/09309 PCT/US00/21192 0 z n64 JL2 viral RNA was used as a negative control and pure JL5 viral RNA was used as a positive control. The pure JL5 sample also served as a control to determine the efficiency of the BssH II enzyme. The MAPREC assay and Squantitation were repeated three times for reproducibility. The results were averaged over the three experiments. Figure 13 shows a representative scanned O gel image. The cleaved and uncleaved products are marked with arrows. The uncleaved product, which corresponds to JL2, is 254 base pairs long while the cleaved product, which corresponds to JLS, is 120 base pairs in length. To quantitate relative abundance for each scanned gel, values were first corrected for background fluorescence and for the amount of undigested DNA in a pure control sample. The JL5 values were determined by dividing the amount of digested DNA by the total of digested and undigested DNA, and by multiplying that value by 100%. For each experiment, RNA from a set of mixed JL5 and JL2 viruses was used to generate a standard curve. The results of the described calculations for the vaccine samples were plotted on the standard curves to obtain the values shown in Table 9. In the final column, the averages for each vaccine sample are given for the three experiments. An overall average for the ten vaccine samples, which was generated by averaging the results in the last column, is shown at the bottom of the table.

Table 9 summarizes the results for the ten vaccine vials of Mumpsvax used in this assay. The relative abundance of the two variants within the vaccine for these samples was in the range of 73.1% JL5/ 26.9% JL2 to 76.1% 23.9% JL2. The overall average for all ten vaccine samples for all three experiments was 73.9% JL5/ 26.1% JL2.

6-AUG.2008 16:36 PHILLIPS ORMOND 6 AG.2UU 1:3 PHuLPS RMNDNO. 617, P. 13 to

;Z

Table 9. Relative abundance of JL5 and 312 in Mnmpsvax samples, MNrkWrLEVAU PWWl~OMt WydM7*02A faos COMS ID No: ARCS-201 170 Received by IP Australia: Time 16:31 Date 2008-08-06

Claims (20)

1. 6. AUG. 2008 16:36 PHILLIPS ORMOND NO. 617 P. 14 0 66 0 SClaims 1. An isolated nucleic acid molecule comprising the consensus sequence of the complete Sgenome or antigenome of Mumps virus, wherein it comprises the sequence of SEQ ID NO:1 in the positive strand, antigenomic message. o 2. An isolated nucleic acid molecule encoding the complete genome or antigenome of Mumps virus, wherein it comprises a sequence in positive strand, antigenomic message sense Sselected from the group consisting of SEQ ID NO: 11 and 12. 10 3. The isolated nucleic acid of claim 2 in which one or more of the genes encoding the Smumps virus proteins NP, P/IV, M, F, SH, HN and L may be variant proteins, wherein: (i) Seach variant retains the function of the corresponding viral protein, (ii) the variant amino acid sequence has at least 70% overall identity to the original viral protein, and (iii) the nucleic acid sequence encoding the variant has at least 70% overall identity to the nucleic acid sequence encoding the original viral protein. 4. The isolated nucleic acid of claim 2 or 3 further comprising an attenuating mutation The isolated nucleic acid molecule according to any one of claims 2 to 4 further comprising one or more heterologous genes or a heterologous nucleotide sequence inserted in a region of the mumps genome sequence selected from: an intergenic region, a non-coding sequence, or a coding sequence of a non-essential gene. 6. The isolated nucleic acid of claim 5, wherein the heterologous genes or nucleotide sequence are contained in a single transcriptional unit.
2. 7. The isolated nucleic acid of claim 6, wherein the transcriptional unit is monocistronic.
3. 8. The isolated nucleic acid of claim 6, wherein the transcriptional unit is polycistronic.
4. 9. The isolated nucleic acid of claim 8, wherein the polycistronic transcriptional unit contains one or more ribosomal entry sites. The isolated nucleic acid of any one of claims 2 to 9, wherein it is a cDNA molecule which upon transcription provides a positive sense version of the mumps genome corresponding to the replicative intermediate RNA (the antigenome). M:iWnsMILSwUV PAwroMs WyewOTvaO atr DOcOBAoe COMS ID No: ARCS-201170 Received by IP Australia: Time 16:31 Date 2008-08-06 6. AUG. 2008 16:36 PHILLIPS ORMOND NO. 617 P. 00 67 0 0 S11. A rescue composition for the recombinant production of mumps virus, which ;Z comprises a transcription vector, comprising a T7 polymerase gene and cDNA according to IN claim 10 placed between a T7 RNA polymerase promoter and a self-cleaving ribozyme o 5 sequence, and (ii) at least one expression vector which comprises polynucleotide sequences encoding the trans-acting proteins (NP, P and L) necessary for encapsidation, transcription and replication of Mumps virus.
5. 12. A method for producing a recombinant mumps virus comprising the transfection or 10 transformation, in media, of at least one host cell with a rescue composition of claim 11, 0
6. 13. The method of claim 12, further comprising the harvesting of the recombinant virus.
7. 14. A recombinant Mumps virus obtainable from the method of claims 12 or 13. An immunogenic composition comprising an isolated recombinant virus according to claim 14.
8. 16. Use of the immunogenic composition of claim 15 in the manufacture of a medicament for immunizing an individual against Mumps virus,
9. 17. The immunogenic composition of claim 15 further comprising at least one antigen of a pathogen other than mumps virus.
10. 18. The immunogenic composition of claim 17 wherein the at least one antigen of a pathogen other than mumps virus is an attenuated RNA virus.
11. 19. The immunogenic composition of claim 18, where the attenuated RNA virus is selected from measles virus, rubella virus, varicella zoster virus, parainfluenza virus, and respiratory syncitial virus. The immunogenic composition of claim 17, wherein the at least one antigen of a pathogen other than mumps virus is produced recombinantly. M MaFILEBAU Pm.7eB WyMVOWs 06an 088.dnt COMS ID No: ARCS-201170 Received by IP Australia: Time 16:31 Date 2008-08-06 6. AUG. 2008 16:36 PHILLIPS ORMOND NO. 617 P. 16 00 68 0 S21 The immunogenic composition of claim 20, wherein the at least one antigen of a pathogen other than mumps virus is expressed from the re inatl rone a ti g en of a Smunmps virus. recombinantly produced attenuated mumps virus.
12. 22. A plamid comprising the nucleic acid of any one of claims to
13. 23. A host cell comprising the plasmid of claim 22. U--
14. 24. The plasmid of claim 22, wherein the transcriptional unit encodes a polyprotein and proteases that cleave said polyprotein to generate the individual polypeptides. A pharmaceutical composition comprising an isolated recombinant virus of claim 13, and a Physiologicaly acceptable carrier.
15. 26. method of immunizing an individual against Mumps virus which comprises administering to a person in need thereof an effecive amount of a composition according to claim 15. 2 7. A nucleic acid according to claim 1 or 2 substantially as hereinbefore described, with reference to any of the Examples
16. 28. A composition according to any one of claims 11, 15 or 25, substantially as hereinbefore described, with reference to any of the Examples.
17. 29. A method according to claim 12 substantially as hereinbefore described, with reference to any of the Examples. A recombinant Mumps virus according to claim 14 substantially as hereinbefore described, with reference to any of the Examples.
18. 31. Use according to claim 16 substantially as hereinbefore described, with reference to any of the Examples.
19. 32. A plasmid according to claim 22 substantially as hereinbefore described, with reference to any of the Exaples. "246LAFILESAV P* aQ'flD CJfte"? MSOq COMS ID No: ARCS-201170 Received by IP Australia: Time 16:31 Date
20. 2008-08-06 6. AUG. 2008 16:36 PHILLIPS ORMOND NO. 617 P. 17 00oo 0 0 O 69 33. A host celI according to claim 23 substantially as hereinbefore described, with reference to any of the Examples. MN:"M hEswAU PmIO6 2edwyl7o6m aOm. cais Mwoo COMS ID No: ARCS-201170 Received by IP Australia: Time 16:31 Date 2008-08-06